IL151321A - Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof - Google Patents

Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof

Info

Publication number
IL151321A
IL151321A IL151321A IL15132102A IL151321A IL 151321 A IL151321 A IL 151321A IL 151321 A IL151321 A IL 151321A IL 15132102 A IL15132102 A IL 15132102A IL 151321 A IL151321 A IL 151321A
Authority
IL
Israel
Prior art keywords
alk
alkyl
radical
azetidin
chlorophenyl
Prior art date
Application number
IL151321A
Other languages
Hebrew (he)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL151321A publication Critical patent/IL151321A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)

Abstract

The invention concerns pharmaceutical compositions containing as active principle a compound of formula (I) wherein: R1 represents a -N(R4)R5, -N(R4)-CO-R5, -N(R4)-SO2R6 radical or one of its pharmaceutically acceptable salts, the novel derivatives of formula (I), their pharmaceutically acceptable salts and their preparation.

Description

15078/02 IJlJDn igiNl Γ ΒΤΝ 7 ID ΓΠ ϋΠΤι miTJ] , ΓΤΊ3ΤΝ 7 ffl UTITJ- Π177Ί3Π ΓΓ '. pn ΓΠΤΠΊΠ PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF The present invention relates to a pharmaceutical composition containing as active ingredient at least one compound of formula: 00 in which • Ri represents a radical selected from-N(R4)R5, -N(R4)-CO-R5, and --NCR4)-- S02 R6, • R2 and R3, which are identical or different, represent either A) an aromatic group selected from phenyl, naphthyl and indenyl, these aromatic groups being unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -- CO-alk, cyano, -COOH, COOalk, -CONR7 Re, -CO-NH-NR9 R10, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl and -alk--NR7 Rs radicals; or B) a heteroaromatic group selected from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3- dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic groups to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, COOalk, - -CO-NH-NR9 Rio, -CONR7 Rs, -alk-NRg Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl and hydroxyalkyl, • R represents a radical selected from-C(Rn)(R12)-Het, -Het, ~(CRn)(Rl2)~ Ar, Ar, cycloalkyl and norbornyl, la Rs represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, -alk--CONR7 Rs, -alk-NR7 Rs, alkoxy, Ar, Het, -CH2 Ar, -CH2 Het and alkyl, said radical being optionally substituted with one or more halogens, Re represents a radical selected from hydroxyalkyl, -alk-COOalk, -alk-CONR7 Rs, -alk-NR7 R8, alkoxy, Ar, Het, -CH2 Ar, -CH2 Het and alkyl, optionally substituted with 1 or more halogens, R7 and Rs, which are identical or different, represent a radical selected from hydrogen and alkyl, or, alternatively, R7 and R8 together form with the nitrogen atom to which they are attached a 3- or 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and io, which are identical or different, represent a radical selected from hydrogen, alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk and hydroxyalkyl or, alternatively, R9 and io together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2 radicals, Rn represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, --alk-CONR Rs, -alk-NR7 Rs, alkoxyalkyl, Ar, Het, -CH2 Ar, -CH2 Het and alkyl, optionally substituted with one or more halogen atoms, Ri2 represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, --alk-CONR7 Rs, -alk-NR7 Rs, alkoxyalkyl and alkyl, optionally substituted with one or more halogen atoms, or alternatively Rn and R12 together form with the carbon atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic ring, optionally containing a heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, lb Ar represents a phenyl, naphthyl or indenyl radical, these different radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, -CO-alk, cyano, --COOH, -COOalk, --CONR13 Ru, --CO--NH--NR15 Rie, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NRis R16, -NR15 R16, alkylthioalkyl, formyl, CF3, OCF3, Het, -0--alk-NH-cycloalkyl, S02 NH2, hydroxyl, hydroxyalkyl, -NHCOalk, and NHCOOalk radicals or, on 2 adjacent carbon atoms, with dioxymethylene, Het represents a 3- or 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, alkoxycarbonyl, oxo or hydroxyl radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form, Ri3 and Ru, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R13 and R14 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ri5 and Ri6, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R15 and i6 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, alk represents an alkyl or alkylene radical, the alkyl and alkylene radicals and portions and the alkoxy radicals and portions being in the form of straight or branched chains and containing 1 to 6 carbon atoms, and the cycloalkyl radicals containing 3 to 10 carbon atoms, the optical isomers of these compounds and their salts with a pharmaceutically acceptable inorganic or organic acid. 151321/1 lc The present invention relates also to a compound of formula: (0 hich • Ri represents a radical -N(R4)R5, -N(R4)-CO-R5, or -N(R )-S02 R6, • R2 and R3, which are identical or different, represent either A) an aromatic group selected from phenyl, naphthyl and indenyl, these aromatic groups being unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, - CO-alk, cyano, --COOH, COOalk, -CONR7 Rs, -CO-NH-NR9 Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl and -alk-NR7 Re radicals; or B) a heteroaromatic ring selected from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3- dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic rings to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, --COOH, COOalk, - -CO--NH--NR9 Rio, -CONR7 Rs, -alk--NR9 Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl and hydroxyalkyl, • R4 represents a radical selected from-C(Rii)(Ri2)--Het, -Het, -(CRn)(R12)-Ar, Ar, cycloalkyl and norbornyl, Id R5 represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, -alk-CONR? Rs, -alk-NE? Rs, alkoxy, Ar, Het, -CH2 Ar, -CH2 Het and alkyl, optionally substituted with one or more halogens, Re represents a hydroxyalkyl, -alk-COOalk, -alk-CONR? Rs, -alk-NR? Rs, alkoxy, Ar, Het, -CH2 Ar, --CH2 Het or alkyl radical optionally substituted with 1 or more halogens, R7 and Rs, which are identical or different, represent hydrogenor alkyl radical or, alternatively, R7 and Rs together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a radical selected from hydrogen, alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk and hydroxyalkyl or, alternatively, R9 and Rio together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2 radicals R11 represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, --alk-CONR7 Rs, -alk-NR7 Rs, alkoxyalkyl, Ar, Het, -CH2 Ar, -CH2 Het and alkyl optionally substituted with one or more halogens, Ri2 represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, --alk-CONR7 Rs, -alk--NR7 Rs, alkoxyalkyl or alkyl optionally substituted with one or more halogens, or alternatively Rn and R12 together form with the carbon atom to which they are attached a 3- to 10-membered saturated mono- or bicychc ring, optionally containing a heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ar represents a phenyl, naphthyl or indenyl radical, these different radicals being optionally substituted with one or more radicals selected from halogen, alkyl, alkoxy, -CO-alk, cyano, --COOH, -COOalk, --CONR13 Ru, --CO--NH--NR15 Ri6, alkylsulfanyl, alkylsuLfinyl, alkylsulfonyl, -alk-NRi5 Ri6, -NR15 Ri6, alkylthioalkyl, formyl, CF3, OCF3, Het, -0»alk»NH-cycloalkyl, S02 NH2, hydroxyl, hydroxyalkyl, -NHCOalk, and NHCOOalk or, on 2 adjacent carbon atoms, with dioxymethylene, Het represents a 3- or 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one ore more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, alkoxycarbonyl, oxo and hydroxyl, the nitrogen- containing heterocycles being optionally in their N-oxidized form, R13 and Ru, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R13 and Ru together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ri5 and Ri6, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R15 and Ri6 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, alk represents an alkyl or alkylene radical, the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain containing 1 to 6 carbon atoms and the cycloalkyl radicals contain 3 to 10 carbon atoms, the optical isomers of these compounds and their salts with a pharmaceutically acceptable inorganic or organic acid, with the exception of benzhydryl-1- cyclopropylamino-3-azetidine dichlorohydrate; 2- [2-((l-(benzhydryl)-azetidine- 3-yl)-2-amino)-phenyl]-ethanol; and l-diphenylmethyl-3-((2- hydroxymethyl)phenylamino)azetidine, as well as any compound in which R2 and R3 represent phenyl radicals, Ri represents a radical -N(R4)S02 R6 in which R4 represents a phenyl radical and R6 represents a methyl radical.
If Related to herein are also pharmaceutical compositions .containing, as active ingredi-ent, at least one compound of formula (I): or one of its pharmaceutically acceptable s-alts, to the novel compounds of formula (I) , to their pharmaceutically acceptable salts and to" their preparation.
The compound of formula (I) for which R¾ and ?-3 represent phenyl radicals, R'i represents a radical -N (PxJ S(-½ $,- EU represents a phen l radical and F.« represents a methyl radical is described as a synthesis Intermedia-te in patent WO 99/01451. The other compounds and their pharmaceutically acceptable salts are novel and as such form parr of the invention.
In the preceding definitions and in those which follow, unless otherwise stated, the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain and contain 1 to 6 carbon atoms and the cycloalkyl radicals contain 3 to 10 carbon atoms.
In formula (I) 2 Ri represents a radical -N(R4)R5, -N (R4) -CO-R5, -N(R4) -S02R6, R2 and R3/ which are identical' or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these · aromatics . being unsubstituted or substituted with one or more halogen atoms or alkyl', alkoxy, formyl, hydroxyl, trifluoromethyl , trifluoro-methoxy, -CO-alk, cyano, -COOH, COOalk, -CONR7R8, -CO-NH-NRgRxo, alkylsulfanyl, alkylsulfinyl , alkylsulfonyl , alkylsulfanylalkyl, alkylsulfinylalkyl , alkylsulfonylalkyl, hydroxyalkyl or -alk-NR7Rs radicals; or a heteroaromatic chosen from benzofuryl, benzothiazolyl , benzothienyl, benzoxazolyl , chromanyl, 2 , 3-dihydrobenzofuryl , 2, 3-dihydrobenzothienyl,. furyl, imidazolyl, isochromanyl , isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1 , 2 , 3 , 4 -tetrahydro— isoquinolyl, thiazolyl ■ and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted with a halogen atom or- an alkyl, alkoxy, hydroxyl, trifluoromethyl , trifluoromethoxy, cyano, -COOH, COOalk, -CO-NH-NR9R10, -CONR7R8, -alk-NRgRio, alkylsulfanyl , alkylsulfinyl , alkylsulfonyl , alkylsulfanylalkyl , alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl radical, R4 represents a radical -C (Ra) (Ri2) -Het , -Het, -(CRU) (R12)-Ar, Ar, cycloalkyl or norbornyl, R5 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR7R8 , -alk-NR7R8-, alkoxy, Ar, Het, 3 -CH2Ar, -CH2Het or alkyl radical optionally substituted with. one or more halogen atoms, R6 represents a hydroxyalkyl, -alk-COOalk, -a.lk-CONR7R8/ -alk-NR7R8, alkoxy, Ar, Het, -CH2Ar, -CH2Het or alkyl radical optionally substituted with 1 or more halogen · atoms , R7 and Re, which are identical or different, .represent a hydrogen atom or an alkyl radical or alternatively R7 and R3 together form with the nitrogen atom to. which they are attached a 3- to 10-membered saturated mono-or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Ri0, which are identical or different, represent a hydrogen atom or an alkyl, -CO.Oalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or alternatively Rg and Rio .together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally, substituted with one or ..more alkyl, -COalk, -COOalk, -CO-NHalk, ' -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or' -CO-NH2 radicals, Rii represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR7R8, -alk-NR7R8, alkoxyalkyl, Ar, Het, -CH2Ar, -CH2Het or alkyl radical optionally substituted with one or more halogen atoms, Ri2 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR7RB, -alk-NRR8, alkoxyalkyl or alkyl radical optionally substituted with one or more halogen atoms, or alternatively Rn and R12 together form with the carbon atom to which they are attached a 3- to -membered saturated mono- or bicyclic ring, optionally containing a heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with. one or more alkyl radicals, Ar represents a phenyl, naphthyl or indenyl radical/ these different radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, -CO-alk, cyano, -COOH, -COOalk, -CONRi3Rn, -CO-NH-NR15R16, alkylsulfanyl, alkylsulfinyl , alkylsulfonyl, -alk-NRisRie r -NR15R16, alkylthioalkyl, formyl, CF3, OCF3, Het, -O-alk-NH-cycloalkyl, S02NH2, hydroxyl, hydroxyalkyl, -NHCOalk, NHCOOalk radicals or on.2 adjacent carbon atoms with dioxymethylene, Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle ' containing one or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, alkoxycarbonyl , oxo or hydroxyl radicals, the nitrogen-containing heterocycles being optionally' in their N-oxidized form, ■ Ri3 and Ri4, which are identical or different, represent a hydrogen atom or an alkyl radical or .■•alternatively R13 and i4 together form with the nitrogen atom to which, they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another he.teroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ri5 and R16, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R15 and R16 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or ■ bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals , alk represents an alkyl or alkylene radical.
In the- preceding definitions and in' those . which follow, unless otherwise stated, the alkyl and . alkylene radicals and portions and the alkoxy radicals and portions are in' the form of a straight or branched chain and contain 1 to 6 carbon atoms and the cycloalkyl radicals contain 3 to 10 carbon atoms.
Among the alkyl radicals, there may be mentioned the methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, iso-butyl, tert-butyl, pentyl and hexyl radicals.. Among the alkoxy radicals, there may be mentioned the methoxy,. ethoxy, n-propoxy, iso-propoxy, 6 n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and pentyloxy radicals.
Among the cycloalkyl radicals,, there may be mentioned the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals.
- The term halogen comprises chlorine, fluorine, bromine and iodine.
Among the heterocycles represented by Het, the following heterocycles may be mentioned: benzimidazole, benzoxazole, benzothiazole, benzothiophene , cinnoline, thiophene, quinazoline, quinoxaline, quinoline, pyrazole, pyrrole, pyridine, imidazole, indole, isoquinoline , pyrimidine, thiazole, thiadiazole, piperidine, piperazine, triazole, furan, tetrahydroisoquinoline, tetrahydroquinoline ,. these ■ heterocycles being optionally substituted with. one or more halogen atoms or alkyl, alkoxy, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3 radicals.
- The compounds of formula (I) may be provided in the form of enantiomers and of diastereoisomers . These isomers and mixtures thereof also form part of the invention.
. . Preferably, the, compounds of formula (I) are those for which Ri. represents a radical -N(R4)R5 or -N (R4 ) -S02Rs, R2 represents either a phenyl which- is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl , trifluoromethoxy, -CO-alk, 7 cyano, -CONR7R8, hydroxyalkyl or -alk-NR7Rs radicals; or a heteroaromatic chosen from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted with a . halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl , trifluoromethoxy, -CONR7R8, -alk-NRgRio, alkylsulfanyl , alkylsulfinyl , alkylsul fonyl or hydroxyalkyl radical, R3 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl , trifluoromethoxy, -CO-alk, cyano, -CONR7R8, hydroxyalkyl or -alk-NR7R8 radicals; or a heteroaromatic chosen from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl , trifluoromethoxy, -CONR7R8,. -alk-NRgRio, alkylsulfanyl , alkylsulfinyl , alkylsulfonyl or hydroxyalkyl radical, R4 represents a radical -C (Ru) (Ri2) -Het, -Het, -C(RU) (Ri2)-Ar, Ar or norbornyl, Rs represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, . -alk-CONR7R8, -alk-NR7R8, alkoxy, -CH2Ar, -CH2Het or alkyl radical, R6 represents a hydroxyalkyl, -alk-COOalk, -alk-CONR7R8, ' -alk-NR7R8, ■ alkoxy, -CH2Ar, -CH2Het or alkyl radical,. R7 and R8, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R7 151321/2 8 and R8 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono-or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals , Rg and Rio, which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or alternatively Rg and Rio together form with the nitrogen atom to which they, are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom chosen' from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, -COOalk, -CO-NHalk, oxo, hydroxyalkyl or -C0-NH2 radicals, Rii represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR7Rs/ -alk-NR7R8, alkoxyalkyl, Ar, Het, -CH2Ar, -CH2Het or alkyl radical optionally substituted with one or more halogen atoms, Ri2 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR7R8, -alk-NR7R8, alkoxyalkyl or alkyl radical optionally substituted with, one or more halogen atoms, or alternatively Ru and Ri2 together form with the carbon atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic ring, optionally containing a heteroatom chosen from oxygen, 9 sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ar represents a phenyl or naphthyl radical, these different radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, -CO-alk, cyano, -CONR13Ri4, alkylsulfonyl , -alk-NRisRi6, -NR15R16,' CF3, OCF3, S02NH2, hydroxyl or hydroxyalkyl radicals or on 2 adjacent carbon atoms with dioxymethylene , Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, oxo or hydroxyl radicals,- the nitrogen-containing heterocycles being optionally in their N-oxidized form and, more particularly, Het represents a heterocycle chosen from benzimidazole, benzoxazole, benzothiazole, benzothiophene , thiophene, quinazoline, quinoxaline, quinoline, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, thi'ad'iazole , furan, tetrahydroisoquinoline and tetrahydroquinoline , these heterocycles being optionally substituted' with one or more halogen atoms or alkyl, alkoxy,. alkoxycarbonyl , oxo, hydroxyl, 0CF3 or CF3 radicals.
Ri3 and R1 , which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively Rx3 and Ri4 together' form with the nitrogen atom to which they are attached a 3- toc 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ri5 and R16, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R15 and Ris together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- . or .bicyclic heterocycle, optionally containing another. heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals . - ' · ' .
Still more preferably, the compounds of formula (I) are chosen from the following compounds: Ri represents a radical -N (R4 ) -S02 6r ∑ represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy,. trifluoromethyl , trifluoromethoxy, cyano, -CONR7R8, hydroxyalkyl or -alk-NR7R8 radicals; or a heteroaromatic chosen from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromati-cs- to be unsubstituted or substituted, with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl , trifluoromethoxy, -CONR7R8 or hydroxyalkyl radical, R3 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, cyano, 11 -CO RT S, hydroxyalkyl or. -alk-NR7R8 radicals; or a heteroaromatic chosen from the pyridyl, pyrimidyl, ■ thiazolyl and thienyl rings, it being possible for ' these heteroaromatics to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxylr trifluoromethyl , trifluoromethoxy, -CONRRa or hydroxyalkyl radical, R4 represents -Het or Ar,' R6 represents a hydroxyalkyl or alkyl radical, R7 and R8, which are identical or different, * represent a hydrogen atom or an alkyl radical or alternatively R7 and R3 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- . or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ar represents a phenyl or naphthyl radical, these different radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, -CO-alk, cyano, -CONRi3Rl / -alk-NRi5Ri6, -NR15R16, F3, OCF3, S02NH2, ■ hydroxyl or hydroxyalkyl radicals, Het represents a 3-' to 10-membered unsaturated or saturated mono- or bicyclic heterocycle- containing one or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl', alkoxy, oxo or hydroxyl radicals, and, more particularly, Het represents a 12 heterocycle chosen from benzimidazole , benzoxazole, benzothiazole, benzothiophene, thiophene, quinazoline, quinoxaline, quinoline, pyrrole, pyridine, imidazole, indole, isoquinoline, thiazole, thiadiazole, furan, tetrahydroisoquinoline and tetrahydroquinoline, these heterocycles being optionally substituted with one or more halogen atoms or alkyl, alkoxy, alkoxycarbonyl, oxo, hydroxyl, OCF3 or.CF3 radicals, ' Ri3 and R14, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R13 and Ri4 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono-or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, .
Ris and R16, which are identical or different, represent a hydrogen atom or- an alkyl radical or alternatively R15 and Ri6 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono-or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or' more alkyl radicals . , Among the preferred compounds, the following compounds may be mentioned: N- { 1- [bis ( 4 -chlorophenyl) methyl] azetidin-3-yl } -N- ( 6-chloropyrid-2-yl) me hylsulfonamide, 13 N- ( 1- [bis ( 4 -chlorophenyl) methyl] azetidin-3-yl } -N- ( 6- ethyIpyrid-2 -y1 ) methylsulfonamide , ' N- { 1- [bis ( 4 -chlorophenyl) methyl] a zetidin-3-yl } -N- quinol-6-ylmethy1sulfonamide, NT- { 1- [bis (4-chlorophenyl) methyl ] azetidin-3-yl } -N- quinol-5-ylmethylsulfonamide N- { 1- [bis (4-chlorophenyl ) methyl] azetidin-3-yl } -N- isoquinol-5-ylmethylsulfonamide, N- { 1- [bis (4-chlorophenyl ) methyl] azetidin-3-yl } -N-pyrid-0 3-ylmethylsulfonamide, N- ( 1- [bis ( -chlorophenyl) methyl] azetidin-3-yl } -N- ( 1- oxide-pyrid-3-yl) methylsulfonamide , N- (lR, 2S, 4S) -bicyclo [2.2.1] hept-2-yl-N- { 1- [bis (4- . chlorophenyl ) methyl] azetidin-3-yl } methylsulfonamide, '5- N-(1R,2R,4S) -bicyclo [2.2.1] hept-2-yl-N- { 1- [bis (4- chlorophenyl) methyl] azetidin-3-yl } methylsulfonamide, N- ( 1- [bis (4-chlorophenyl ) methyl] azetidin-3-yl } -N- (3,5- difluorophenyl ) methylsulfonamide, N- { 1- [bis ( 4 -chlorophenyl) methyl] azetidin-3-yl } -N-0 (thiazol-2-yl) methylsulfonamide , N- { 1- [bis (4-chlorophenyl ) methyl] azetidin-3-yl } -N- (3- methoxyphenyl) methylsulfonamide, N- { 1- [bis (4-chlorophenyl ) methyl ] azetidin-3-yl } -N- ( 3- hydroxyphenyl ) methylsulfonamide, N- ( 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl } -N- ( 3- hydroxymethylphenyl ) methylsulfonamide , Ethyl N- ( 1- [bis ( 4-chlorophenyl ) methyl ] azetidin-3-yl } -N- (methylsulfonyl ) -3-aminobenzoate , 14 N- { 1- [bis ( 4-chlorophenyl) methyl] azetidin-3-yl } -N- ( 1-isob.utylpiperid-4 -yl ) me hylsulfonamide , N-benzyl-N- { 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl } amine, N- { 1- [bis ( 4-chlorophenyl) methyl] azetidin-3-yl } -N- (3, 5-difluorobenzyl ) amine, N-{1- [bis (4-chlorophenyl).methyl] azetidin-3-yl } -N- (3, 5-difluorobenzyl ) methylsulfonamide, N- { 1- [bis ( 4-chlorophenyl) methyl] azetidin-3 -yl } -N-(pyrid-3-ylmethyl ) methylsulfonamide N- { 1- [bis ( -fluorophenyl) methyl] azetidin-3 -yl } -N- (3,5-difluorophenyl ) methylsulfonamide, (RS) -N- { 1- [ (4-chlorophenyl) pyrid-3-ylmethyl ] azetidin-3 yl } -N- ( 3 , 5-difluorophenyl) methylsulfonamide, (R) -N— { 1- [ (4-chlorophenyl ) pyrid-3-ylmethyl ] azetidin-3-yl } -N- ( 3 , 5-difluorophenyl) methylsulfonamide, (S) -N- { 1- [ (4-chlorophenyl) pyrid-3-ylmethyl ] azetidin-3-yl }—N- (3 , 5-difluorophenyl ) methylsulfonamide , (RS) -N- (.1- [ (4-chlorophenyl) pyrid-4 -ylmethyl ] azetidin-3 yl} -N- (3, 5-difluorophenyl) methylsulfonamide, (R) -N-{ 1- [. (4-chlorophenyl) pyrid-4 -ylmethyl ] azetidin-3-yl} -N- (3, 5-difluorophenyl) methylsulfonamide, (S) -N-{1- [ (.4-chlorophenyl) pyrid-4 -ylmethyl ] azetidin-3-yl } -N- (3 , 5-difluorophenyl ) methylsulfonamide , (RS) -N- { 1- [ (4-chlorophenyl) pyrimid-5- lmethyl ] azetidxn 3-yl } -N- ( 3 , 5-difluorophenyl ) methylsulfonamide , (R) -N- { 1- [ ("4-chlorophenyl) pyrimid-5 -ylmethyl ] azetidin-3-yi}-N- (3, 5-difluorophenyl) methylsulfonamide, (S) -N- { 1- [ (4-chlorophenyl) pyrimid-5-ylmethyl ] azetidin-3-yl}--N- (3, 5-difluorophenyl) methylsulfonamide, N- { 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl } -N- (3 , 5-difluorophenyl ) benzylsulfonamide,. their optical isomers and their pharmaceutically acceptable salts.
The compounds of formula (I) for which Ri represents the radical -N(R4)R5 in which R5 is a hydrogen atom, a radical -N(R4)-CO-R5 or -N (R4 ) -S02R6,. 4 is a radical -C(Ru) (Ri2)-Ar or -C(Rn) (Ri2)-Het and R12 is a hydrogen atom may be prepared according to the following reaction scheme: Γ 16 In these formulae, ∑ , R3 R6 and Rn have the same meanings as in formula (I), Rb represents an Ar or Het radical, Ar and Het having the same meanings as in. formula (I) and Hal represents a halogen atom and preferably chlorine or bromine. ■ .
Step a is 'generally carried out in an inert solvent such as tetrahydrofuran , dioxane, a · chlorinated' solvent (for example dichloromethane or chloroform), at a temperature of between 15 and 30 °C, in the presence of a base such as a trialkylamine (for example 17 triethylamine or dipropylethylamine ) or -in pyridine, at a temperature of between 0 and 30 °C.
Step b is preferably carried out in methanol, in' an autoclave, at a- temperature of between 50 and 70°C.
Step c is generally carried out in an inert solvent such as a chlorinated solvent (for example dichloromethane) , in the presence of sodium triacetoxyborohydride and acetic acid, at a temperature in the region of 20°C.
Steps d and e are generally carried out in an inert solvent such:, as tetrahydrofuran, dioxane, a chlorinated solvent (for example dichloromethane or chloroform) , in the presence of an amine- such as a t.rialkylamine (for example triethylamine), at a temperature of between 5°C and 20°C.
The derivatives Rb-CORn are commercially available' or may be obtained according to the methods described for example by R.C. LAROCK, Comprehensive Organic Transformations, VCH editor.
The derivatives Hal-S02R6 are commercially available or may be obtained by halogenation of the corresponding sulfonic acids, in particular in situ in .the presence of chlorosulfonyl isocyanate and alcohol, in a halogenated solvent (for example dichloromethane' ' or chloroform) .
The derivatives Hal-CORs are commercially available or may be prepared by halogenation of the 18 corresponding carboxylic acids, in particular in situ in the presence of thionyl chloride in a halogenated solvent (for example dichloromethane or chloroform) .
The azetidinols 1 may be obtained by application or ■ adaptation of the methods described by KATRITZKY A.R. et al . , J. Heterocycl .. Chem. , 271 (1994) or DAVE' P. R., J. Org. Chem., 61, 5453 (1996) and in the examples. The procedure is generally carried out according to the following reaction scheme: in these formulae, R2 and R3 have the same meanings as in formula ( I ) and Hal represents a chlorine or bromine atom. 19 In step A the procedure is preferably carried out in an inert solvent such as a 1-4C aliphatic alcohol (for example ethanol or methanol), optionally in the presence of an alkali metal hydroxide, at the boiling point of the reaction medium.
In step B, the reduction is generally carried out, by means of lithium' aluminum hydride, in tetrahydrofuran at the boiling point of the reaction medium.
In step C,. the procedure is preferably carried out in an inert solvent such as a 1-4C aliphatic alcohol (for example ethanol or methanol), in the presence of sodium hydrogen carbonate, at a temperature of between 20°C and the boiling point of the reaction medium.
In step D, the procedure is carried out according . to the method described, by GRISAR M. et al . in J. Med. Chem., 885 (1973) . The magnesium compound of the brominated derivative is formed and then the ■20' nitrile is caused to react, in an ether such as ethyl ether, at a temperature of between 0°C and the boiling point of the reaction medium. After hydrolysis with an alcohol, the intermediate imine is reduced in situ with sodium borohydride at a temperature of between 0°C and the boiling point of the reaction medium.
The derivatives R2-CO-R3 are commercially available or may be obtained by application or adaptation of the methods described by KUNDER N.G. et al. J. Chem. Soc. Perkin Trans 1, 2815 (1997); MORENO- MARRAS M., Eur.. J. Med. Chem., 23 (5) 477 (1988); SKINNER et al- , J. Med. Chem., 14 (6) 546 (1971); • HURN . K . ,. Tet. Lett., 36 (52) 9453 ( 1995 ); MEDICI A. et al., Tet. Lett., 24_ (28) 2901 (1983); RIECKE R.D. et al., J. Org. Chem., 62 (20) 6921 (1997); KNABE J. et al., Arch. Pharm., 3_0_6 (9) 648 (1973); CONSONNI R. et al., J. Chem. Soc. Perkin Trans 1, 1809 (1996);.
FR-96-2481 and JP-94 -261393.
The derivatives R3Br are commercially available or may be. obtained by application or adaptation of the methods described by BRANDSMA L. et al., Synth. Comm., 20 (11) 1697 and 3153 (1990); LEMAIRE M. et al . , Synth. Comm., 2_4 (1) 95 (1994); GODA H. et al . , Synthesis,' 9 849 (1992); BAEUERLE P. et al., J. Chem. Soc. Perkin Trans 2, 489 (1993) .
The derivatives R2CN are commercially available or may be' obtained by application or adaptation of the methods described by BOQYSSOU P. et al., J. Het. Chem., 2_9 (4) 895 (1992); SUZUKI N . et . al.., J. Chem. Soc. Chem.. Comm., 1523 (1984); MARBURG S. et al., J. Het. Chem., 17 1333 (1980); PERCEC V. et al., J. Org. Chem., .60 (21) '6895 (1995) .
The compounds of formula (I) for which Rj. represents a radical -N(.R4)Rs may be prepared according to the following reaction scheme: 21 In these formulae, R2, R3, R and R5 have the same meanings as in formula- (I) .
This reaction is generally carried out in an inert solvent such as a chlorinated solvent (for example dichloromethane) , in the .presence of sodium triacetoxyborohydride and acetic acid, at a temperature in the region of 20°C.
The compounds HN(R4)Rs are commercially available or may be prepared according to conventional methods known to persons skilled in the art or by application or adaptation of the methods described by Park K.K. et al., J. Org. Chem., 60 (19) 6202 (1995); Kalir A. et a.l.., J. Med. Chem., 12 (3) 473 .(1969)'; Sarges R., J. Org. Chem., 40 (9) 1216 (1975); Zaugg H.E. , J. Org. Chem.,. 3_3 (.5) 2167 (19.68); Med. Chem., 10, 128 (.1967); J. Am. Chem. Soc . , .2244 (1955); Chem. Ber., 106,.2890 (1973); Chem. Pharm. Bull., 16, . (10) 1953 (1968); Bull. Soc. Chim. Fr . , 835 (1962).
The azetidinones 2 may be obtained by oxidation of the corresponding acetidinols, preferably in dimethyl sulfoxide, by means of the sulfur trioxide-pyridine complex., at a temperature in the region of 22 °C or by means of dimethyl sulfoxide, in the presence of oxalyl chloride and triethylamine, at a temperature of between -70°C and -50°C.
The compounds of formula (I) for which Rj. represents a radical -N(R4)COR5 or -N(R )S02R6 may be prepared according to the following reaction scheme: In these formulae,. R2, 3, R4 , R5 and R6 have the same meanings as in formula (I) and Hal represents a halogen atom and preferably chlorine.
Steps a and b are generally carried out in an inert solvent such as tetrahydrofuran , dioxane, a chlorinated solvent (for example dichloromethane or chloroform), in the presence of an amine such as a trialkylamine (for example triethylamine) , at a temperature of between 5°C and 20°C.
The compounds of formula (I) for which 'Ri represents a radical -N (R4 ) -S02-R6 for which R4 is a Het 23 or Ar radical may be prepared according to the following reaction scheme: In these formulae, R2, R3 and R.6 have the same meanings as in formula (I), Rd represents an Ar or Het radical (Het and Ar having the same meanings as in formula (I)) and Ms - represents a methylsulfonyloxy radical .
Step a-' is generally carried out in an inert solvent such as tetrahydrofuran, in the presence of triphenylphosphine and diethylazodicarboxylate , at a temperature of between 0°C and the boiling point of the reaction . medium.
Step b is generally carried out in an inert solvent such as tetrahydrofuran, dioxane, a chlorinated solvent (for example dichloromethane or chloroform), at a temperature of between 15°C and 30°C, in the presence of a base such as a trialkylamine (for example 24 triethylamine or dipropylethylamine) or in pyridine, at a temperature of between 0°C and 30°C.
Step c is preferably carried out in an inert solvent such as dioxane in the presence of CsC03, at the reflux temperature of the reaction mixture.
The derivatives for which . d represents an N-oxidized nitrogen-containing heterocycle may be reduced [lacuna] nonoxidi.zed compound according to the method described by SA GHANEL E. et 'al .,. Synthesis 1375 (1996) .
The derivatives Rd-NH-S02R6 niay be obtained according to the following reaction scheme: Hal-S02-R6 d-NHj — - Rd-NH-S02-R6 In these formulae, Hal represents a halogen atom, Rd represents a Het or Ar radical. The reaction is carried out in an inert solvent such as. tetrahydrofuran, dioxane, a chlorinated solvent (for example dichloromethane or chloroform) , at a temperature of between 15°C and 30°C, in the. presence of a base such as a trialkylamine (for example triethylamine or dipropylethylamine) or in pyridine, at a temperature of between 0°C and 30°C.
The derivatives for which Rd represents an N-oxidized nitrogen-containing heterocycle may be obtained according to the method described by RHIE R., Heterocycles, 41 (2) 323 (1995) .
■The compounds of formula (I) may also be prepared according to the following reaction scheme: R2-CO-R3 R3Br + R2-CHO a b R„-CHOH-R., In these formulae, i, R2 and R3 have the same meanings as in formula (I) and Ph represents a phenyl .
Step a is generally carried out in an alcohol such as methanol, in the presence of sodium borohydride, at a temperature in the region of 20°C.
In step b, the magnesium compound of the brominated derivative is prepared and it is caused to. react, in an inert solvent such as ethyl ether or tetrahydrofuran, at a temperature of between 0°C and the boiling point of the reaction medium. ■ 26 Step c is carried out by means of a halogenating agent such as hydrobromic acid, thionyl bromide, thionyl chloride, a mixture of ■ ■ triphenylphosphine and carbon tetrabromide .or tetrachloride,- in acetic acid or an inert solvent such · as dichloromethane, chloroform, carbon tetrachloride or toluene, at a temperature of between 0°C and the boiling point of the reaction medium.
Step d is carried out by means of hydrogen, in the presence of palladized charcoal, in an alcohol such as methanol, at a temperature in the region of 20°C.
Step e is carried out in an inert solvent such as acetonitrile, in the presence of an alkali metal carbonate (for example potassium carbonate) and potassium iodide, at a temperature of between 20°C and the boiling point of the reaction medium.
The derivatives R3Br and the derivatives R2-CHO are commercially available or may be obtained according to the methods described for example by R.C. LAROCK, Comprehensive Organic Transformations, VCH. editor.
The compounds of formula (I) for which Ri represents a radical -N (R4) -SO2- 6 for which R is a 4-piperidyl radical optionally substituted on the nitrogen with- an alkyl radical may also be prepared according to the following reaction ' scheme :■ 27 In these formulae, R2, R3 and Re have the same meanings as in formula (I), alk . represents an alkyl radical and Re represents a tert-butylcarbonyloxy radical .
Step a is carried out in an inert solvent such as a chlorinated solvent (for example dichloromethane ) , in the presence of a hydride such as sodium triacetoxyborohydride and acetic acid, at a temperature of between 0°C and the boiling point of the-reaction medium.
Step b is generally carried out . in an inert, solvent such as' tetrahydrofuran, dioxane, a chlorinated solvent (for example dichloromethane or chloroform) , in 28 the presence of an amine such as a trialkylamine ( tri.ethylamine for example), at a temperature of between- 5°C and 20°C.
Step c is carried out by means of hydrochloric acid, in dioxane, at a temperature of between 0°C and the boiling point of the reaction medium.
Step d is carried out by any means known to persons skilled in the art for alkylating an amine without affecting the rest of the molecule. It is possible, for example, to use an alkyl halide, in the presence of an organic base such as triethylamine or an alkali metal hydroxide (.for example sodium hydroxide or potassium hydroxide) , optionally in the presence of tetrabutylammonium bromide, in an inert solvent such as dimethyl sulfoxide, dimethylformamide or pyridine, at a temperature of between 20 and 50°C.
The. compounds of formula (I) for which Rx represents a radical -N ( R4 ) -S02-Rg for which R is a phenyl radical substituted with a 1-pyrrolidyl radical may also be prepared by the action of pyrrolidine on a corresponding compound of formula (I) for which Ri represents, a. radical -N(R4)S02R6 for which R4 is a phenyl radical substituted with a halogen atom.
This reaction is preferably carried out in dimethyl sulfoxide, at a temperature of between 50 and 95°C. 29 It is understood for persons skilled in the art that, to carry out the processes according to the invention which are described above, it may be necessary to introduce groups protecting amino, hydroxyl and carboxyl functions in order to avoid side reactions. These groups are those which allow removal without affecting the rest of the molecule. As examples of groups protecting the amino function, there may be mentioned tert-butyl or methyl carbamates which may be regenerated using iodotrimethylsilane or allyl using palladium catalysts. As examples of groups protecting the hydroxyl function, .there may be mentioned triethylsilyl and tert-butyldimethylsilyl which may be regenerated using tetrabutylammonium fluoride or alternatively asymmetric acetals (methoxymethyl or tetrahydropyranyl for example) with regeneration using hydrochloric acid. As groups protecting carboxyl functions, there may be. mentioned esters (allyl or benzyl for example), oxazoles and 2-alkyl-l,3-oxazolines. Other' protecting groups which can be used' are described by GREENE T.W. et al . , Protecting Groups in Organic Synthesis, second edition, 1991, John Wiley & Sons .
The compounds of formula (I) may be purified by the customary known methods, for example by crystallization, chromatography or extraction.
The enantiomers of the compounds of formula (I) may be obtained by resolution of the racemates for example by chromatography on a chiral column according to P.IRCKLE W.H. et al . , Asymmetric synthesis, Vol. I, Academic Press (1983) or by formation of salts or by synthesis from chiral precursors. The diastereoisomers may be prepared according to known conventional methods (crystallization, chromatography or from chiral precursors) .
The compounds of formula (I) may be optionally converted to addition salts with an inorganic or organic acid by the action of such an acid in an organic solvent such as an alcohol, a ketone, an ether or a chlorinated solvent. These salts also form part of the invention.
As examples of pharmaceutically acceptable salts,, the following salts may be mentioned: benzenesulfonate , hydrobromide, hydrochloride, citrate, ethanesulfonate, fumarate, gluconate, iodate, isethionate, maleate, methane sulfonate, methylene-bis-b-oxynaphthoate , nitrate, oxalate, pamoate, phosphate, salicylate, succinate, sulfate, tartrate, ' theophyllineacetate and p-toluenesulfonate .
The compounds of formula (I) exhibit advantageous pharmacological properties. These compounds possess a high affinity for the cannabinoid receptors and particularly those of the CBl type. They are CBl receptor antagonists and are therefore useful in the treatment and prevention of disorders affecting the central nervous system, the immune system, the 31 cardiovascular or endocrine system, the respiratory system, the gastrointestinal apparatus and reproductive disorders (Hollister, Pharm. Rev.; 38, 1986, 1-20, Reny and Sinha, Prog. Drug Res., 36, 71-114 (1991), Consroe and Sandyk, in Marij uana/Cannabinoids , Neurobiology- and Neurophysiology, 459, Murphy L. and Barthe A. Eds, CRC Press, 1992) .
Accordingly, these compounds may be used for the treatment or prevention of psychoses including schizophrenia, anxiety disorders, depression, epilepsy, neurodegeneration, cerebellar and spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheral neuropathies, glaucomas, migraine, Parkinson's disease, Alzheimer ' s- disease, Huntington's chorea, Raynaud's syndrome, tremor, obsessive-compulsive disorder, .senile dementia, thymic disorders, Tourette's syndrome, tardive dyskinesia, bipolar disorders, cancers, movement disorders induced by medicaments, dystonia, endotoxemic shocks, hemorrhagic shocks, hypotension, insomnia, immunological diseases, multiple sclerosis, vomiting, asthma, appetite disorders (bulimia, anorexia), obesity, memory disorders, in weaning from chronic treatments and alcohol or drug abuse .(opioids, barbiturates, cannabis, cocaine, amphetamine, phencyclide, hallucinogens, benzodiazepines for example) , as analgesics or potentiators of the analgesic activity of the narcotic 32 and nonnarcotic- drugs. They may also be used for the treatment or prevention of intestinal transit.
The affinity of the compounds of formula (I) for the cannabis receptors has been determined according, to the method described by KUSTER J.E., STEVENSON J.I., WARD S.J., D'AMBRA T.E., HAYCOCK D.A. in J. Pharmacol. Exp. Ther., 264 1352-1363 (1993).
In this test, the IC50 of the compounds of formula (I) is less than or equal to 1000 nM.
Their antagonist activity has been shown by means of the model of hypothermia induced by an agonist of the cannabis receptors (CP-55940) in mice, according to the method described by Pertwee R.G. in Marijuana, Harvey D.J. eds, 84 Oxford IRL Press, 263-277 (1985).
In this test, the ED50 of . the compounds of formula (I) is less than or equal to 50 mg/kg.
The compounds of formula (I) exhibit low toxicity. Their LD50 is greater than 40 mg/kg by the ■ subcutaneous route in mice.
. The following examples illustrate the invention.
Example 1 N- { 1- [Bis- ( 4-chlorophenyl ) methyl] azetidin-3- yl } -N- ( 6-chloropyrid-2-yl ). methylsulfonamide may be prepared by carrying out the procedure in the following manner: 2.4 cm3 of diethyl azodicarboxylate and 1.44 g of triphenylphosphine are added, under argon, to a solution of 1.54 g of 1- [bis ( 4 -chlorophenyl ) methyl ] - 33 azetidin-3-ol and 1.22 g of N- ( 6-chloropyrid-2- yl ) methyisulfonamide in 120 cm3 of anhydrous tetrahydrofuran . After stirring for 20 hours at 20°C, the react ion . mixture is concentrated to dryness under reduced pressure (2.7 kPa) . The residue is chromatographed on a silica gel column (particle size 0.040-0.063 mm, height 30 cm, diameter 4.5 cm) , eluting under an argon pressure of 0.5 bar with a mixture of - cyclohexane and ethyl acetate (80/20 by volume) and collecting 60-cm3 fractions. Fractions 6 to 9 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 1.75 g of N- { 1- [bis ( 4-chloro- phenyUmethyl] azetidin-3-yl } -N- ( 6-chloropyrid-2-yl ) - methylsulfonamide are obtained in the form of a white foam [lH NMR spectrum (300 MHz, CDC13> δ in ppm) : from 2.85 to 3.00 (mt : 2H) ; 2.91 (s : 3H) ; 3.57 (split t, J = 7 and 2 Hz : .2H) ; 4.25 (s : 1H) ; 4.64 (mt : 1H) ; from 7.20. to 7.35 (mt : 9H) ; 7.36 (d , J = 8 and 1 Hz :. 1H) ; 7.71 it, J; = .8 Hz : 1HH · 1- [Bis ( 4-chlorophenyl) methyl] azetidin-3-ol may be prepared according to the procedure described by KATRITZKY A.R. et al . , J. Heterocycl. Chem. , 271 (1994) , starting with 35.5 g of [bis ( 4-chlorophenyl )"- methyl] amine hydrochloride and 11.0 cm3 of epichloro- hydrin. 9.0 g of 1- [bis (4-chlorophenyl ) methyl] azetidin- 3-ol are isolated. 34 Bis (4 -chlorophenyl) methyl] amine hydrochloride may be prepared according to the method described by GRISAR M. et al . , J. Med. Chem., 885 (1973) .
N- ( 6-Chloropyrid-2-yl) methylsulfonamide may be prepared by- carrying out the procedure in the following manner: 7.8 cm3 of methylsulfonyl chloride are poured dropwise, over 1 hour, into a solution, cooled to +5°C, of 2-amino-6-chloropyridine in 12.5 cm3 of pyridine.. After returning to room temperature and stirring for 20 hours, the black reaction mixture is supplemented with 140 cm3 of water and extracted with 200 cm3 of dichloromethane . The organic . phase is separated after settling, dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) . The oily residue obtained is chromatographed on a silica gel column (particle size 0.063-0.200 mm, height 30 cm, diameter 4 cm), eluting under an argon pressure of 0.5 bax with a mixture of; cyclohexane and ethyl acetate (70/30 by volume) and collecting 60-cm3 fractions . Fractions 5 to 11 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 17 g of N- ( 6-chloropyrid-2-yl ) methylsulfonamide are obtained in the form of a yellow oil .
Example 2 N- { 1- [Bis (4 -chlorophenyl) methyl] azetidin-3 -yl } -N- ( 6-ethylpyrid-2-yl ) methylsulfonamide may be prepared by carrying out the procedure as described in Example 1, starting with 0.61 g of l-[bis(4- .chlorophenyl) methyl] azetidin-3-ol , 0.40 g of N-(6-■ ethylpyrid-2-yl) methylsulfonamide, 50 cm3 of anhydrous tetrahydrofuran, 0.96 cm3 of diethyl azodicarboxylate and 0.577 g of- triphenylphosphine . The crude product is chromatographed on a silica gel column (particle size 0.040-0.063 mm, height 20 cm, diameter 2 cm), eluting. under an argon pressure of 0.5 bar with a mixture of ■ cyclohexane and ethyl acetate (70730 by volume) and collecting 30-cm3 fractions. Fractions 6 to 9 are combined and concentrated to, dryness under reduced pressure (2.7 kPa) . 0.3 g of an oil is obtained which is triturated in a mixture of 5 cm3 of diethyl ether and 5 cm3 of diisopropyl ether. The suspension is filtered, the solid drained and then dried under reduced pressure (2.7 kPa) . 0.11 g of N- { 1- [bis ( 4-chlorophenyl) methyl] - azetidin-3-yl } -N- ( 6-ethylpyrid-2-yl ) methylsulfonamide is obtained in the form of a. white solid [1H N R spectrum (300 MHz, CDC13, δ in ppm) : 1;26 (t, J = 7.5 Hz. : 3H) ; 2.76 (q, J = 7.5 Hz : 2H) ; from.2.85 to 2.95 (mt : 2H) ; 2.90 (s : 3H) ; 3.53' (split t, J = 7 and 2 Hz : 2H) ; 4.22 (s : 1H) ; 4.69 (mt : 1H) ; 7.07 (d, J = 7.5 Hz : 1H) ; from 7.15 to 7.30 (mt : 9H) ; 7.64 (t, J = 7.5 Hz : 1H) ] .
N- ( 6-Ethylpyrid-2-yl) methylsulfonamide may be prepared by carrying out the procedure in the following manner: 1.56 cm3 of methylsulfonyl chloride are poured dropwise into a solution, cooled to +5°C, of 2.50 g of 36 2-amino-6-ethylpyridine in 2.50 cm3 of pyridine. After stirring for 20 hours at 20°C, the reaction mixture is supplemented with 8 cm3 of water and filtered. The. filtrate is concentrated to dryness at 50°C under reduced pressure (2.7 kPa) . The residue is chromatographed on a silica gel column (particle, size 0.040-0.063 mm, height 30 cm, diameter 4 cm), eluting under an argon pressure of 0.5 bar with 1.5 litres of dichloromethane and then with a . mixture of dichloro-methane and methanol (98/2 by volume) and collecting 60-cm3 fractions. Fractions 8 to 12 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 2.8 g of N- (6-ethylpyrid-2-yl) methyl-sulfonamide are obtained in the form of a yellow oil. Example 3 N- { 1- [Bis ( 4 -chlorophenyl ) methyl] azetidin-3-yl } -N-quinol-6-.ylmethylsulfonamide may be prepared by carrying out .the procedure .in t.he following manner: 0..70 g of 1- [bis ( 4 -chlorophenyl ) methyl] azetidin-3-ol and 0.597 g of triphenylphosphine are added, under argon, to a solution of 0.50 g of N-quinol-6-ylmethyl-sulfonamide in 50 cm3 of anhydrous tetrahydrofuran and then 0.40 cm3 of diethyl azodicarboxylate is poured in. After stirring for 20 hours at 20°C, the reaction mixture is heated at the reflux temperature for 4 hours and then supplemented with 2.98 g of triphenylphosphine and 2.0 cm3 of diethyl azodicarboxylate. After stirring for 48 hours at 20°C, the mixture is concentrated to 37 dryness under reduced pressure (2.7 kPa) . The residue is taken up i 30 cm3 of diethyl ether, the suspension obtained is filtered and the filtrate is concentrated to dryness. A fraction of the residue obtained (0.90 g) is purified on- a Bond Elut column of cation exchange sulfonic acid SCX resin (particle size 0.054 mm, height 4 cm, diameter 3 cm) , eluting first with methanol and then with a 2 M solution of aqueous ammonia in methanol in order to elute the expected product, collecting 5-cm3 fractions. Fractions 16 to 19 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 0.33 g of an oil is obtained which is stirred in 10 cm3 of diisopropyl ether. The resulting suspension is filtered. The filtrate, which is again filtered, gives, after 15 minutes, a solid which is dried at 50°C under reduced pressure (2.7 kPa) . 83 mg of N- ( 1- [bis ( 4-chlorophenyl ) methyl] azetidin-3-yl } -N-quinol-6-ylmethylsulfonamide are obtained in -the form of a white solid [XH NMR spectrum ( 300 · MHz , CDC13, δ in ppm) : 2.87 (s : 3H) ; 2.89 (mt : 2H) ; 3.55 (split t, J = 7 and 1 Hz : 2H) ;. 4.18 (s : 1H) ; 4.69 (mt : 1H) ; from 7.15 to 7.30 (mt : 8H) ; 7.47 (dd, J = 8.5 and ' 4 Hz : 1H) ; 7.58 (dd, J = 9 and 2.5 Hz : 1H) ; 7.73 (d, J = 2.5.Hz : 1H); 8.10 to 8:20 (mt : 2H) ; 8.97 (dd, J = 4 and 1.5 Hz : 1H) ] N-Quinol-6-ylmethylsulfonamide may be prepared by carrying out the procedure in the following manner: 1.1 cm3 of methylsulfonyl chloride are poured 38 ■ dropwise, over 1 hour, into a solution, cooled to +3°C, of 1..98 g of 6-aminoquinoline in 1.75 cm3 of pyridine. After stirring for 20 hours at 20°C, the reaction mixture is supplemented with 10 cm3 - of water and 50 cm3 of dichloromethane, and then filtered. The filtrate is separated after settling, the organic phase is dried over magnesium sulfate, and then filtered and concentrated to dryness under reduced pressure (2.7 kPa) . 1.15 g of N-quinol-6-ylmethylsulfonamide are obtained in the form of a cream-yellow solid.
Example 4 N- { 1- [Bis ( 4-chlorophenyl) methyl ].azetidin-3-yl } -N-quinol-6-ylmethylsulfonamide may be prepared by carrying out the procedure in the following manner: 0.70 g of 1- [bis ( -chlorophenyl ) methyl] azetidin-3-ol and 0.597 g of triphenylphosphine are added, . under argon, to a solution of 0.50 g of N- (quinol-5-yl) -methylsulfonamide in .70 cm3 of anhydrous tetrahydrofuran and then 0.40 cm3 of diethyl azodicarboxylate and 0.45 g of 1, 2-bis (diphenylphosphine) ethane are poured in.
After stirring for 20 hours at 20°C, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) . The residue is taken up in 70 cm3 of e hyl acetate, the resulting solution is washed with 30- cm3 of brine, dried over magnesium sulfate, filtered and then concentrated to dryness at 50°C under reduced pressure (2.7 kPa)' . The violet oil obtained is purified by chromatography on a silica gel column (particle size 39 0.063-0.200 mm, height 35 cm, diameter 3.9 cm), eluting under an argon pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (40/60 then 30/70 and 20/80 by volume) and collecting 50-cm3 fractions.
Fractions 6 to 12 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . The residue is taken up in 15 cm3 of methanol, the resulting white suspension is filtered, the solid drained and then dried at 50°C under reduced pressure (2.7. kPa) . 0.35 g of N- { 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl } -N- quinol-5-ylmethylsulfonamide is obtained in the form of a white solid [XH NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.60 (t, J = 7 Hz : 1H) ; 2.84 (t, J = 7 Hz : 1H) ; 2.99 (s : 3H) ; 3.36 (split t, J = 7 and 2.5 Hz : 1H) ; 3.56 (split t, J = 7 and 2.5 Hz : 1H) ; 4.01 (s : lH) ; 4.85 (mt : 1H) ; from 7.10 to 7.25 (mt : 8H) ; 7.40 (dd, J = 7.5 and 1 Hz : 1H) ; 7.54 (dd, J = 8.5 and 4 Hz : . . 1H) ; 7.74 (dd, J = 8 and 7.5 Hz : 1H) ; 8.20 (broad d, J ' = 8 Hz : 1H) ; 8.54 (broad d, J = 9 Hz : 1H) / 8.99 (dd, J = 4 and 1.5 Hz : 1H) ] .
N- (Quinol-5-yl) methylsulfonamide may be prepared by carrying out the procedure as described in Example 3, starting with 2.0 g of 5-aminoquinoline , 3.0 cm3 of pyridine, 1.1 cm3 of methylsulfonyl chloride. 2.4.7 g of N- (quinol-5-yl) methylsulfonamide are obtained in the form of a brown-yellow solid. 40 Example 5 N- { 1- [Bis ( 4 -chlorophenyl) methyl] azetidin-3- yl } -N-isoquinol-5-ylmethylsulfonamide may be prepared by carrying out the procedure as described in Example 4, starting, with 0.497 g of N- ( isoquinol-5-yl ) methy1- sulfonamide, 70 cm3 of anhydrous tetrahydrofuran, 0.712 g of 1- [bis ( 4-chlorophenyl ) methyl ] azetidin-3-ol , 0.597 g of triphenylphosphine, 0.40 cm3 of diethyl azodicarboxylate and 0.45 g of 1 , 2-bis ( dipheny-1- phosphine) ethane . The crude brown oil obtained is purified by chromatography on a silica gel column (particle size 0.063-0.200 mm, height 38 cm, diameter 3 cm) , eluting with a mixture of cyclohexane and ethyl acetate (30/70 by volume) and collecting 40-cm3 fractions. Fractions 8 to 23 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . The residue. is stirred in 15 cm3 of diethyl ether, the suspension is filtered and the insoluble matter is chromatographed on a column of SCX resin (height 4 cm, diameter 3' cm) , washing first with a mixture of methanol and dichloromethane (50/50 by volume) and then eluting with a 2 M solution of aqueous ammonia in methanol and- collecting 20-cm3 - fractions . Fractions 1 to' 6 are combined and the white insoluble matter which appears is filtered, the solid is drained and then dried at 50°C under reduced pressure ■ (2.-7 kPa) . 0.169 g of N- { 1- [bis ( 4 -chlorophenyl ) methyl ]' - azetidin-3-yl } -N-isoquinol-5-ylmethylsulfonamide is 41 obtained in the form of a white solid [1H NMR spectrum (300. MHz, CDCI3, δ in ppm) : 2.64 (t, J = 7 Hz : 1H) ; 2.81 (t, J = 7 Hz : 1H) ; 2.98 (s : 3H) ; 3.36 (split t, J = 7 and 2. Hz : 1H) ; 3.55 (split t, J = 7 and 2 Hz : 1H); 4..02 (s : 1H) ; 4.86 (mt : 1H) ; from 7.10 to .7.25 (mt : 8H) ; 7.60 (dd, J = 8 and 1 Hz : 1H) ; 7.66 (t, J = 8 Hz : 1H) ; 7.93 (broad d, J = 6 Hz : 1H) ; 8.06 (broad d, J = 8 Hz : 1H) ; 8.66 (d, J = 6 Hz : 1H) ; 9.32 (broad s : 1H) ] .
' N- ( Isoquinol-5-yl) methylsulfonamide may be prepared by carrying out the procedure as described in Example 4, starting with 2.0 g of 5-aminoisoquinoline, 3.0 cm3 of pyridine and 1.1 cm3 of methylsulfonyl chloride. 2.3 g of - ( isoquinol-5-yl ) methylsulfonamide are obtained in the form of a beige solid.
Example 6 N- { 1- [Bis ( 4-chlorophenyl ) methyl ] azetidin-3-yl } -N-pyrid-3-ylmethylsulfonamide may be prepared, by carrying out the procedure in the following manner: 0.042 cm3 of phosphorus trichloride is poured into a solution of 0.144 g of N- ( 1- [bis ( 4 -chlorophenyl ) -methyl] azetidin-3-yl } -N- ( l-oxide-pyrid-3-yl ) methyl -sulfonamide in 5 cm3 of chloroform and then the mixture is heated to the reflux temperature. After stirring for 1 hour 30 minutes, the reaction mixture is allowed to return to room temperature and is then supplemented with 5 cm3 of 0.1 N hydrochloric acid, then stirred and . separated after settling. The organic phase is- diluted 42 with 20 cm3 of chloroform, dried over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) . The residue is chromatographed on a silica gel column (particle size 0.063-0.200 mm, height 9 cm, diameter. 1.8 cm), eluting under an argon pressure of 0.1 bar with a mixture of dichloromethane and methanol (95/5 by volume) and collecting 15-cm3 fractions. Fractions 2 to 4 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . The residue is stirred with 15 cm3 of diethyl ether, the suspension is filtered, the solid is drained and then dried under reduced pressure (2.7 kPa) . 35 mg of N- { 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl } -N-pyrid-3-ylmethylsulfonamide are obtained in the form of a cream-coloured solid [XH NMR spectrum (300 MHz, CDC13, δ in ppm) : from 2.80 to 2.95 (mt : 2H) ; 2.87 (s : 3H) ; 3.51 (split t, J = 7 and 1.5 Hz : 2H) ; 4.18 (s :. 1H) ; 4.65- (mt. : 1H) ; from 7.15 to 7.35 (mt : 8H) ;■ 7.37 (broad dd, J = 8 and 5 Hz : 1H) ; 7.64 (decoupled d, J = 8 Hz : 1H) ; 8.52 (broad d, J_= 2 Hz : 1H) ; 8.61 (broad d, J = 5 Hz : 1H) ] .
Example 7 N- { 1- [Bis (4-chlorophenyl) methyl] azetidin-3-yl}-N- (l-oxide-pyrid-3-yl) methylsulfonamide may be" prepared by carrying out the procedure in the following manner: 0.16 cm3 of diethyl azodicarboxylate and 0.226 g of triphenylphosphine are added, under argon, to a solution. of 0.265 g of .1- [bis ( 4-chlorophenyl) methyl] - 43 azetidin-3-ol and 0.162 g of N- ( l-oxide-pyrid-3-yl) methylsulfonamide, in 25 cm3 of anhydrous tetrahydro-furan. After stirring for 20 hours at 20°C, and then for 24 hours at the reflux temperature, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) . The residue is chromatographed on a silica gel column (particle size 0.063-0.2 mm, height 20 cm, diameter 1.5 cm), eluting under an argon pressure of 0.5 bar with a mixture of dichloromethane and methanol (98/2 by volume) and collecting 40-cm3 fractions. Fractions 26 to 64 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . The residue is stirred in 10 cm3 of diethyl ether, the suspension is filtered, the insoluble matter is drained and then dried under reduced pressure- (2.7 kPa) . 0.1 g of N- { 1- [bis ( 4 -chlorophenyl ) methyl ] -azetidin-3-yl } -N- ( l-oxide-pyrid-3-yl ) methylsulfonamide is' obtained in the form of a white solid [1H NMR spectrum (400, MHz, (CD3)2SO d6, δ in ppm) : 2.78 (t, J = 7 Hz : 2H) ; 3.06 (s : 3H) ; 3.37 (t, J = 7 Hz : 2H) ; 4.45 (s : 1H) ; 4.71 (mt : 1H) ; from 7.30 to 7.50 (mt : 10H) ; 8.21 (broad d, J = 6.5 Hz : 1H) ; 8.27 (broad s :' 1H) ] .
N- ( l-Oxide-pyrid-3-yl ) methylsulfonamide may be prepared by carrying out the procedure in the following manner: 7.1 g of 50-55% 3-chloroperoxybenzoic acid are added, in fractions, to a solution of 1.81 g of N-pyrid-3-ylmethylsulfonamide in 71 cm3 of 44 N, N-dimethylformamide and 3 cm3 of methanol, followed by 0.56. cm3 of 40'% hydrofluoric acid. After stirring for 1 hour at 20°C, the reaction mixture is poured into 500 g of ice, stirred and then filtered. The filtrate is concentrated to dryness at 60°C under reduced pressure (2.7 kPa) . The residue is taken up in 50 cm3 of a mixture of dichloromethane and methanol (98/2 by volume) and then filtered. The filtrate is chromatographed on a silica gel column (particle size 0.063-0.2 mm, height 27 cm, diameter 4 cm), eluting under an argon pressure, of 0.5 bar with a mixture of dichloromethane and methanol (98/2, 97/3 and then 50/50 by volume) and collecting. 60-cm3 fractions. Fraction 62 is concentrated to dryness under reduced pressure (2.7 kPa) . 0.96 g of N- ( l-oxide-pyrid-3-yl ) methy1-sulfonamide is obtained in the form of a yellowish solid.
N-Eyr.id-3-ylmethylsulfonamide may be prepared by carrying out the procedure as described in Example 1, starting with 2 g of 3-aminopyridine, 5 cm3 of pyridine and 1.8 cm3 of methylsulfonyl chloride. The crude product obtained is stirred in 40 cm3 of diethyl ether, the suspension is filtered and then the solid is drained and dried under reduced pressure (2..7 kPa) . 2.4.7 g of N-pyrid-3-ylmethylsulfonamide are obtained in the form of a pinkish solid. 45 Example 8 N- { 1- [Bis ( 4-chlorophenyl ) methyl ]azetidin-3-yl } -N-cyclohexylmethylsulfonamide may be prepared by carrying out the procedure in the following manner: 0.4 cm3 of methylsulfonyl chloride is added, with stirring, to a solution of 1.8 g.of N-{l-[bis(4-chlorophenyl ) methyl ]azetidin-3-yl} -N-cyclohexylamine , 0.7 cm3 of triethylamine and 20 mg of 4-dimethylamino-pyridine in 25 cm3 of dichloromethane . After stirring for 48 hours at 20°C, 20 cm3 of dichloromethane. and cm3 of water are added to the reaction mixture and it is stirred and separated after settling. The organic phase is dried over magnesium sulfate and concentrated at 5.0 °C under reduced pressure (2.7 kPa) . The brown oily residue is chromatographed on a silica gel column (particle size 0.063-0.2 mm, height 20 cm, diameter 2.0 cm), eluting under an argon pressure of 0.1 bar with a mixture of dichloromethane and methanol (96/4 by volume) and collecting 10-cm3 fractions. Fractions 2 to 4 and 5 to 10 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . The residue is chromatographed on a silica gel column (particle size 0.063-0.2 mm, height 30 cm, diameter 1.5 cm), eluting under an argon pressure of 0.1 bar with a mixture of cyclohexane and ethyl acetate (70/30 by volume), and collecting 5-cm3 f actions. Fractions 7 to 10 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 0.10 g of N- { 1- [bis ( 4 -chloro- 46 phenyl) methyl] azetidin-3-yl } -N-cyclohexylmethyl-sulfonamide is obtained in the form of a . cream-coloured foam [xti NMR spectrum (300 MHz, CDC13, δ in ppm) : from 0.80 to 1.90 (mt : 10H) ; 2.82 (s : 3H) ; 3.36 (broad t, J = 7.5 Hz : 2H) ; 3.46 (broad t, J = 7.5 Hz : 2H) ; 3.59 (mt : 1H) ; 4.08 (mt : 1H) ; 4.'42 (s : 1H) ; from 7.20 to 7.40 (mt : 8H) ] .
N- { 1- [bis ( -chlorophenyl) methyl] azetidin-3-yl } -N-cyclohexylamine may be prepared by carrying out the procedure in the following manner: 0.5 g of cyclohexylamine, .1 g of sodium triacetoxyborohydride and 0.3 cm3 of 100% acetic acid are added to a solution of 1.5 g of 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3-one in 25 cm3 of 1 , 2-dichloroethane . After stirring for 20 hours at 20°C, 20 cm3 of dichloromethane and 10 cm3 of water are added to the reaction mixture, with stirring, and then the mixture is neutralized to pH 7 to 8 with a 1 N aqueous sodium hydroxide solution. The mixture: is separated after settling, the organic phase is dried over magnesium sulfate and concentrated to dryness at 50°C under reduced pressure (2.7 kPa). 1.8 g of N-{1-[bis ( 4 -chlorophenyl ) methyl] azetidin-3-yl } -N-cyclohexylamine are obtained in the form of a cream-coloured paste which will be used as it is in the next step. 1- [Bis (4-chlorophenyl) methyl] azetidin-3 -one may be prepared according to the following procedure: a solution of 8.1 cm3 of dimethyl sulfoxide in 17.6 cm3 of dichloromethane is added to a solution of 5.0 cm3 of 47 oxalyl chloride in 73 cm3 of dichlorome hane cooled to -78°C. After 0.5 hour at -78°C, a solution of 16.0 g of 1- [bis (4-chlorophenyl) methyl] azetidin-3-ol, dissolved in 50 cm3 of dichloromethane, is poured in. After 5 hours at -78 °C, 26.6 cm3 of triethylamine are added dropwise and the reaction mixture is allowed to return to room temperature. After 16 hours, the reaction, mixture is washed with 4 times 200 cm3 of water and then with 200 cm3 of a saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) . The residue obtained is chromatographed on a silica gel column (particle size 0.04-0.06 mm, diameter 9.2 cm, height 21 cm), under an argon pressure of 0.5 bar with a mixture of ethyl acetate and cyclohexane (40/60 by -volume) as eluents and collecting 200-cm3 fractions . Fractions 15 to 25 are combined and then concentrated to dryness under reduced pressure. (2.7 kPa) . 8.9 g of 1- [bis (4-chlorophenyl) methyl] azetidin-3-one are obtained in the form of pale yellow crystals melting at 111°C.
Example 9 N- { 1- [Bis (4-chlorophenyl ) methyl] azetidin-3-yl } -N-cyclopropylmethylsulfonamide may be prepared by carrying out the procedure as described in Example 8, starting with 1.6 g of N- { 1- [bis ( 4 -chlorophenyl) -methyl] azetidin-3-yl } -N-cyclopropylamine , 25 cm3 of dichloromethane, ' 0.7 cm3 of triethylamine, 20 mg of 4- 48 dimethylaminopyridine and 0.4 cm3 of methylsulfonyl chloride, while the mixture is stirred for 20 hours at 20°C. The crude product is chromatographed on a silica -gel column (particle size 0.063-0.2 mm, height 30 cm, diameter 2.0 cm), eluting under an argon pressure of 0-.1 bar with a mixture of dichloromethane and methanol (97/3 by volume) and collecting 10-cm3 fractions.
Fractions 6 to 9 and 10 to 20 are combined and concentrated to dryness under reduced pressure (2.-7 kPa) . The residue obtained is chromatographed on a silica gel column (particle size 0.063-0.2 mm, height 30 cm, diameter 2.0 cm), eluting under an argon pressure of 0.1 bar with a mixture of cyclohexane and ethyl acetate (70/30 by volume) and collecting 10-cm3 fractions. Fractions 6 to 11 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 0.14 g of N- { 1- [bis ( 4 -chlorophenyl ). methyl ] - a.zetidin-3-yl }, -N-cyclopropylmethylsulfonami.de is obtained in the form of a cream-coloured foam [1H NMR spectrum (300 MHz, CDCI3, δ in ppm) : 0.79 (mt : 2H) ; 0.95 (mt : 2H) ; 2.11 (mt : 1H) ; 2.84 (s : 3H) ; 3.17 (broad t, J = 7 Hz : 2H); 3.50 (mt : 2H) ; 4.18 (mt : 1H) ; 4.29 (s : 1H) ; from 7.20 to 7.40 .(mt : 8H) ] .
N- { 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3- yl } -N-cyclopropylamine may be prepared by carrying out the procedure as described in Example 8, starting with 1.5 g of 1- [bis ( 4-chlorophenyl ) methyl] azetidin-3-one , 25 cm3 of 1, 2-dichloroethane, 0.37. cm3 of 49 .cyclopropylamine , 1 g of sodium triacetoxyborohydride and .0.3 cm3 of 100% acetic acid. 1.6' g of N- { 1- [bis ( -chlorophenyl ) methyl] azetidin-3-yl } -N-cyclopropylamine are obtained in the form of a brown oil which will be used as it is in the next step.
Example 10 N- (1R, 2S,4S) Bicyclo [2.2.1] hept-2 -yl-N- ( 1- [bis ( 4 -chlorophenyl ) methyl ]azetidin-3-yl} methyl-sulfonamide may be prepared by carrying out the procedure as described in Example 8, starting with 2.0 g of N-(lR,2S,4S)bicyclo[2.2.1]hept-2-yl-N-{l- [bis ( 4-chlorophenyl) methyl] azetidin-3-yl } amine, 25 cm3 of dichloromethane, 0.7 cm3 of triethylamine , 20 mg of 4 -dimethylaminopyridine and 0.4 cm3 of methylsulfonyl chloride, with stirring for 20 hours. The brown oily residue is chromatographed on a' silica gel column (particle size 0.063-0.2 mm, height 30 cm, diameter 2.0 cm), eluting under an argon pressure of 0.1 bar with a mixture of dichloromethane and methanol (97/3 by volume) and collecting 10-cm3 fractions. Fractions 6 to 18 are combined and concentrated to dryness under reduced pressure (2.7 kPa). The residue is chromatographed on a silica gel column (particle size 0.063-0.2 mm, height 30 cm, diameter 2.0 cm), eluting under an argon pressure of 0.1 bar with a mixture of cyclohexane and ethyl acetate (70/30 by volume) and collecting 10-cm3 "fractions . Fractions 8 to 14 are combined and concentrated to dryness under reduced 50 pressure (2.7. kPa) . 0.70 g of N- (1R, 2S, 4S ) bicyclo- [2.2 , 1] hept-2-yl-N- { 1- [bis ( 4-chlorophenyl) methyl] -azetidin-3-yl }methylsulfonamide is obtained in the form of a cream-coloured foam [XH NMR spectrum (30.0 MHz, CDCI3 , δ in ppm) : from 1.20 to 1.75 (mt : 7H) ; 1.84 (broad t , J = 12.5 Hz : 1H) ; 2.29 (mt : 1H) ; 2.35 (mt -: 1H) ; 2.82. (s : 3H) ; from 3.35 to 3.55 (mt : 3H) ; 3.66 (mt : 1H) ; from 3.90 to 4.05 (mt : 2H) ; 4.51 (s : 1H) ; from 7.20 to 7.45 (mt : 8H) ] .
N- (1R, 2S, 4S) Bicyclo [2.2.1] hept-2-yl-N- ( 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3-yl } amine may be prepared by carrying out the procedure as described in Example 8, starting with 1.5 g of 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3-one , 25 cm3 of 1, 2-dichloro-ethane, 1.5 g of ( 1R, 2S , 4 S ) bicyclo.[ 2.2.1 ] hept-2-yl-amine, 1 g of sodium triacetoxyborohydride and 0.3 cm3 of 100% acetic acid. 2 g of N- ( 1R, 2S , 4S ) bicyclo [ 2.2.1] --hept-2-yl-N- (1- [bis (4-chlorophenyl) methyl] azetidi.n-3-yl}amine are obtained in the form of a' brown oil which will be used as it is in the next step.
Example 11 N- (1R, 2R, 4S) Bicyclo [2.2.1] hept-2-yl-N- { 1- [bis. ( 4 -chlorophenyl ) methyl] azetidin-3-yl Jmethylsulfonamide may be prepared by carrying out the procedure as described in Example 8, starting with 1.8 g of N-(lR,2R,4S)bicyclo[2.2.1]hept-2-yl-N.-{l- [bis (4-chlorophenyl) methyl] azetidin-3-yl } amine , 25 cm3 of dichloromethane, 0.7 cm3 of triethylamine, 20 mg of 51 4-dimethylaminopyridine and 0.4 cmJ of methylsul fonyl chloride, with stirring for 20 hours. The brown oily residue is chromatographed on a silica gel column (particle size 0.063-0.2 mm, height .30 cm, diameter 2.0 cm), eluting under an argon pressure of 0.1 bar with a mixture of cyclohexane and ethyl acetate (60/40 by volume) and collecting 10-cm3 fractions. Fractions .3 to 12 are combined and concentrated to dryness under reduced pressure (2.7.kPa) . The residue. is chromatographed on a silica gel column (particle size 0.063-0.2 mm, height 30 cm, diameter 2.0 cm), eluting under an argon pressure of 0.1 bar with, a mixture of cyclohexane. and ethyl acetate (70/30 by volume) and collecting 10-cm3 fractions. Fractions 4 to 10 are combined and concetrated to dryness under reduced pressure (2.7 kPa) . 0.10 g of N- ( 1R, 2R, S ) bicyclo- [2.2.1] hept-2-yl-N-{ 1- [bis (4-chlorophenyl) methyl] -azetidin-3-yl }methylsulfonamide is obtained in ..the form of a yellow foam [XH NMR spectrum (300- MHz, CDC13, δ in ppm) : from 1.00 to 1.85 (mt : 8H) ; 2.14 (mt : 1H) ; 2.33 (mt : 1H) ; 2.82 (s .: 3H) ; from 3.40 to 3.60 (mt : 4H) ; 3.71 (broad dd, J = 8 and 6 Hz : 1H) ; 4.10 (mt : 1H).; 4.47 (s : 1H) ; from 7.20 to 7.40 (mt : 8H) ] .
N- (1R, 2R, 4S) Bicyclo[2.2.1] hept-2-yl-N- { 1-[bis ( 4-chlorophenyl ) methyl] azetidin-3-yl } amine may be prepared by .carrying out the procedure as described in Example 8, starting with 1.5 g of 1- [bis ( -chlorophenyl ) methyl] azetidin-3-one, 25 cm3 of 1, 2-dichloro- 52 ethane, 0.6 g of ( 1R, 2R, 4 S ) bicyclo [ 2.2.1 ] hept-2- ylamine, 1 g of sodium triacetoxyborohydride and 0.3 cm of 100%'acetic acid. 1.8 g of N- (1R, 2R, S) bicyclo- [2.2.1] hept-2-yl-N- { 1- [bis ( 4 -chlorophenyl ) methyl ] - aze'tidin-3-yl } amine are obtained in the form of a cream-coloured paste which will be used as it is in the next step.
Example 12 N- [ ( 1-Benzhydryl) azetidin-3-yl] -N-phenyl- methylsulfonamide may be prepared by carrying out the procedure in the following manner: 0.7 cm3 of methyl- sulfonyl chloride is poured into a solution of 2 g of l-benzhydryl-3-anilinoazetidine in 40 cm3 of dichloro-■■ methane and then 1.34 cm3 of triethylamine are added. ■ After stirring. for 4 hours and 15 minutes at 20°C, the' • reaction mixture is washed with twice 20 cm3 of water, the organic phase is dried over magnesium sulfate and then concentrated to dryness at 50°C under reduced pressure (2.7 kPa) . The brown oil obtained is ■ chromatographed on a silica gel column (particle size 0.063-0.2 mm, height 26 cm, diameter 3.6 cm), eluting under an argon pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (70/30 by volume) and collecting 50-cm3 fractions. Fractions 10 to- 15 are combined and concentrated to dryness under reduced pressure (2.7 kPa) , the residue is triturated in diethyl ether, the suspension is filtered, -the solid is drained and then dried under reduced pressure 53 (2.7 kPa) . 35 mg of N- [ ( 1-benzhydryl) azetidin-3-yl] -N-phenylmethylsuifonamide are obtained in the form of a white solid [l NMR spectrum (300 MHz , (CD3)2SO do with addition of a few- drops of CD3COOD d4, δ in ppm) : 2.72 (mt : 2H) ; 2.9-2 (s : 3H) ; 3.36 (mt : 2H) ; 4.32 (s : 1H) ; 4.73 (mt : 1H) ; from 7.10 to 7.45 (mt : 15H) ] . l-Benzhydryl-3-anilinoazetidine may be prepared by carrying out the procedure as described in Example 8, starting with 5 g of l-benz.hydrylazetidin-3-one, 1.92 cm3 of aniline, 74 cm3.of 1, 2-dichloroethane, 6.3 g of sodium triacetoxyborohydride and 1.2 cm3 of 100% acetic acid. 8.81 g of l-benzhydryl-3-anilinoazetidine are obtained in the form of a brown gum which will be used as it is in the next step.
Example 13 N- { 1- [Bis (4-chlorophenyi) methyl] azetidin-3-yl } -N- ( 3 , 5-difluorophenyl ) methylsulfonamide may be prepared- by carrying out the procedure in the following manner: 1.0 g of cesium carbonate is added to a mixture of 1.23 g of 1- [bis (4 -chlorophenyl ) methyl ] azetidin-3-yl methylsulfonate and 0.66 g of N- ( 3 , 5-difluorophenyl ) -methylsulfonamide, in 25 cm3 of dioxane. After stirring, for 5 hours at the reflux temperature, and then for 20 hours at 20 °C, the reaction mixture is supplemented with 50 cm3 of diethyl ether and 30 cm3 of brine, and is then stirred and separated after, settling. The organic phase is dried over- magnesium sulfate, filtered and then concentrated to dryness at 50°C under reduced 54 pressure (2.7 kPa) . The orange-colored oil obtained is chromatographed on a silica gel column (particle size 0.040-0.063 mm, height 25 cm, diameter 2.0 cm), eluting under an argon pressure of 0.5 bar with a mixture- of cyclohexane and ethyl acetate (65/35 by volume) and collecting 10-cm3 fractions. Fractions 6 to 10 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . The residue is chromatographed on a silica gel column (particle size 0.040-0.063 mm, height 15 "cm, diameter 1.0 cm), eluting under an argon pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (65/35 by volume) and collecting 5-cm3 fractions. Fraction 7 is concentrated to dryness under reduced pressure (2.7 kPa) . 0.11 g of N-{l-[bis(4-chlorophenyl ) methyl] a∑etidin-3-yl } -N- ( 3 , 5-difluoro-phenyl ) methylsulfonamide is obtained in the form of a white powder [:H NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.82 (s : 3H) ; 2.85 (mt : 2H) ; 3.5-2 '( split t ■, J = 7 and 2 Hz : 2H) ; 4.22. (s_: 1H) ; 4.47 (mt : 1H) ; from 6.75 to 6.90 (mt : 3.H) ; from 7.20 to 7.35 (mt : 8H) ] . Method 2 0.78 cm3' of diethyl azodicarboxylate and 1.31 g of triphenylphosphine are added, under argon, to a solution of 1.41 g of 1- [bis (4-chlorophenyl) -methyl] azetidin-3-ol and 0.95 g of N- ( 3-, 5-difluoro-phenyl) methylsulfonamide in 100 cm3 of anhydrous tetrahydrofuran . After stirring for 16 hours at 20°C, 300 cm3 of ethyl acetate are added, the reaction mixture 55 is washed twice with 100 cm3 of water, dried over magnesium sulfate and concentrated to dryness under reduced pressure (2.7 kPa) . The residue is chromatographed on a silica gel column (particle size 0.20-0.063 mm, · height 50 cm, diameter 4 cm) , eluting under an argon pressure of 0.6 bar with a mixture of cyclohexane and ethyl acetate (75/25 by volume) and collecting 125-cm3 fractions. Fractions 6 to 12 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 1.8 g of a solid are obtained, which solid is dissolved hot in an ethyl acetate/diisopropyl ether (15/2 by volume) mixture, cooled and diluted with 100 cm3 of pentane in. order to initiate the crystallization. After filtration and drying, 1.0 g of N-{1- [bis (4-chlorophenyl)methyl] -azetidin-3-yl } -N- ( 3 , 5 -difluorophenyl ) methylsulfonamide is obtained in the form of white crystals melting at 154°C. ' N- ( 3 , 5-Difluorophenyl ) methylsulfonamide may be prepared by carrying, ou the procedure in the following manner: 2.0 cm3 of methylsulfonyl chloride, 3.8 cm3 of ■ triethylamine and 20 mg of 4-dimethylamino-pyridine are slowly added to a solution of 3.5 g of 3 , 5-difluoroaniline in 75 cm3 of dichloromethane. After stirring for 20 hours at 20°C, the reaction mixture, supplemented with 20 cm3 of dichloromethane and 20 cm3 of water, is stirred- and then separated after settling. The organic phase is dried over magnesium sulfate, 56 filtered and then concentrated to dryness under reduced pressure (2.7 kPa) . The residue is chromatographed on a .silica gel column (particle size 0.063-0.200 mm, height 20 cm, diameter 2.0 cm), eluting under an argon pressure of 0.1 bar with dichloromethane and collecting 2.5-cm3 fractions. Fractions 14 to 20 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 0.66 g of N- (3, 5-difluorophenyl)-methyl-sulfonamide is obtained in the form of a white powder. * 1- [Bis ( 4-chlorophenyl ) methyl ] azetidin-3-yl methyl sulfonate may be prepared by carrying out the procedure in the- following manner: 3.5 cm3 of methyl-sulfonyl chloride are added, under argon and over 10 minutes, to a solution of .12 g of 1- [bis ( -chloro-phenyl ) methyl ] azetidin-3-ol in 200 cm3 of dichloromethane, then the mixture, is cooled tfo +5°C and 3.8 cm3 of pyridine are poured in over 10 minutes. After stirring for 30 minutes at +5°C and then for 20 hours at 20°C, the reaction mixture is diluted with 100 cm3 of water and 100 cm3 of dichloromethane. The mixture, which is first filtered, is separated after settling. The ■ •organic phase is washed with water, then dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) . The .oil obtained is chromatographed on a silica gel column (particle size 0.063-0.200 mm, height 40 cm, diameter 3.0 cm), eluting under an argon pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (70/30 by volume) and 57 collecting 100-cm3 fractions. Fractions 4 to 15 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 6.8 g of 1- [bis ( 4 -chlorophenyl ) -methyl ] azetidin-3-yl methyl sulfonate are obtained in the form of a yellow oil. 1- [Bis ( 4 -chlorophenyl) methyl] azetidin-3-ol may be prepared according to the procedure described by KATRITZKY A.R. et al . , J. Heterocycl . Chem. , '271 (1994), starting , with 35.5 g of [bis ( 4 -chlorophenyl) - · methyl] amine hydrochloride and 11.0 cm3 of epichloro-hydrin. 9.0 g of 1- [bis ( -chlorophenyl ) methyl ] azetidin-3-ol are isolated.
[Bis (4-chlorophenyl)methyl] amine hydrochloride may be prepared according to the method described by GRISAR M. et al . , J. Med. Chem., 885 (1973) .
Example 14 N- { 1- [Bis ( 4 -chlorophenyl ) methyl] azetidin--3-yl } -N- ( 4 , 6-dimethylpyrimid-2-yl ) methylsulfonamide may be prepared by carrying out the procedure as described in Example 13 (method 2), starting with 0.20 -g of N— ( 4 , 6-dimethylpyrimid-2-yl ) methylsulfonamide and 0.308 g of 1- [bis ( -chlorophenyl) methyl] azetidin-3-ol . After chromatography on a silica gel column (particle size 0.06-0.04 mm, height 50 cm, diameter 2 cm) , . eluting under an argon pressure of 0.6 bar with dichloromethane and then a mixture of dichloromethane + 1% methanol and then a mixture of dichloromethane + 2% methanol and 58 collecting 200-cm3 fractions, fractions 4 to 7 ar;e combined and concentrated to dryness under reduced pressure (2.7 kPa) . After crystallization from diisopropyl ether, filtration and drying, 0.20 g of N- { 1- [bis (4-chlo-rophenyl ) methyl] azetidin-3-yl } -N- (4,6-dimethylpyrimid-2-yl) methylsulfonamide is obtained in the form of a white solid [XH NMR spectrum (300- MHz, CDC13, δ in ppm) : 2.39 (s : 6H) ; 2.89 (broad t, J = 7.5 Hz : 2H) ; 3.51 (s ': 3H) ; 3.77 (mt :.2H); 4.27 (s :, 1H); 4.77 (mt : 1H) / 6.73 (s : 1H) ; from 7.20 to 7.35 (mt : 8H) ] .
N- ( , 6-Dimethylpyrimid-2-yl ) methylsulfonamide may be prepared by carrying out the procedure in the following manner: 1.4 cm3 of triethylamine are added, at 0°C, to a mixture of 1.23 g of 2-amino-4 , 6-dimethyl-pyrimidine, 0.77 cm3 of methylsulfonyl chloride and 50 mg of 4 -dimethylaminopyridine dissolved in 50 cm3 of dichloromethane . After 16 hours at room temperature, the reaction medium is washed with twice 100 cm3 of water, dried over magnesium sulfate, filtered and then evaporated to dryness under reduced pressure (2.7 kPa) . 1.0 g of a yellow powder is obtained which is treated with 15 cm3 'of 10% sodium hydroxide at 100°C for 1 hour. After cooling, the reaction mixture is extracted with twice 50 cm3 of dichlo.romethane . The aqueous phase is acidified to pH = 1 with 5 cm3 of 10 N hydrochloric acid and extracted with twice 50 cm3 of dichloromethane. The organic phases obtained are combined, washed with 50 cm3 59 of water, dried over magnesium sulfate, filtered and concentrated. Ό.20 g of N- ( 4 , 6-dimethylpyrimid-2-yl ) -methylsulfonamide is obtained in the form of a yellow powder.
Example 15 N- { 1- [Bis ( 4-chlorophenyl) methyl] azetidin-3-yl } -N- ( 1 , 3 , 4-thiadiazol-2-yl) methylsulfonamide may be prepared by carrying out the procedure as described in Example 13 (method 2), from 0.10 g of N-(l,3,4- . thiadiazol-2-yl) methylsulfonamide and 0.215 g of 1- [bis ( -chlorophenyl) methyl] azetidin-3-ol . After chromatography on a silica gel column (particle size 0.06-0.04 mm, height 25 cm, diameter 1 cm), eluting under an argon pressure of 0.8 bar with an ethyl acetate/cyclohexane 20/80 and then 40/60 by volume mixture and collecting 60-cm3 fractions, fractions 26 to 31 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . After- crystallization from diisopropyl ether, filtration and drying, 40 mg of N-(l-[bis (4-chlorophenyl)methyl]azetidin-3-yl}-N-(l, 3,4-thiadiazol-2-yl ) methylsulfonamide are obtained in the form of a white solid [XH NMR spectrum (300 MHz , CDC13, δ in ppm) : 3.01 (s : 3H) ; 3.09 (split , J = 7 and 1.5 Hz : 2H) ; 3.70 (split t, J = 7 and 1.5 Hz : 2H) ; 4.28 (s : 1H) ; 4.76 (mt : 1H) ; from 7.20 to 7.35 (mt : 8H) ; 9.01 (s : 1H) ] .
N- ( 1 , 3 , 4-Thiadiazol-2-yl ) methylsulfonamide may be prepared by carrying out the procedure in the 60 following manner: 1.5 cm3 of methylsulfonyl chloride are added. to a mixture of 2.02 g of 2 -amino-1, 3, 4-thiadiazole in 10 cm3 of pyridine. After 2 hours at room temperature, 60 cm3 of water are added and the reaction medium is filtered. The aqueous phase collected is acidified to pH = 2 with 1 N hydrochloric acid, extracted with twice 50 cm3 of ethyl acetate, the . organic phase washed with twice 50 cm3 of water, dried over magnesium sulfate, filtered and then evaporated to dryness under reduced pressure (2.7 kPa) . 0.1 g of a yellow powder is obtained.
Example 16 N- { 1- [Bis ( -chlorophenyl) methyl] azetidin-3-yl } -N- ( thia∑ol-2-yl) methylsulfonamide may be prepared by carrying out the procedure as described in Example 15, starting with 0.50 g of N- ( hiazol-2-yl ) methylsulfonamide and 0.5 g of 1- [bis ( 4-chlorophenyl) -methyl] azeti.din.-3-ol . After chromatography on. a silica gel column (particle size 0.06-0.04 mm, height 60. cm, diameter 2 cm) , eluting under an argon pressure of 0.9 bar with an ethyl acetate/cyclohexane 20/80 and then 40/60 by volume mixture and collecting 30-cm3 fractions, fractions 9 to 12 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . After crystallization from diisopropyl . ether, ' filtration and drying,. 0.21 g of N-{l-[bis(4-chlorophenyl) methyl] azetidin-3-yl } -N- ( thiazol-2-yl ) methylsulfonamide is obtained in. the- form of a white 61 solid NMR spectrum (300 MHz, CDC13, δ in ppm) : from 2.95. to 3.10 (mt : 2H) ; 3.00 (s : 3H) ; 3.59 (mt : 2Ή) ; 4.22 (broad s : 1H) ; 4.69 (mt : 1H) ; from 7.20 to 7.35 (mt : 9H) ; 7.60 (mt : 1H) ] .
N- (Thiazol-2-yl) methylsulfonamide may be- prepared by carrying out the procedure in the following manner: 1.15 g of methylsulfonyl chloride are added to a mixture of 1.0 g of 2-aminothiazole in 5 cm3 of pyridine. After 2 hours at room temperature,. 20 cm3 of water are added, the reaction medium is filtered and the solid collected (0.35 g) . The aqueous phase collected is acidified to pH = 2 with 1 N hydrochloric acid, extracted with twice 40 cm3 of ethyl acetate, the organic phase washed with twice 30 cm3 of water, dried over magnesium sulfate, filtered and then evaporated to dryness under reduced pressure (2.7 kPa) . 0.15 g of a white solid is obtained which has spectral characteristics -similar to the filtered solid • corresponding to an N- ( thiazol-2-yl ) methylsulfonamide and N- ( thiazol-2-yl ) di (methylsulfonyl) imide mixture which is used as it is for the next step.
Example 17 N- { 1- [Bis ( 4-chlorophenyl ) methyl] azetidin-3- yl.} -N- ( 3-hydroxyphenyl ) methylsulfonamide may be prepared by carrying out the procedure in the following ■manner: 7.63 cm3 of a 1 M boron tribromide solution are added dropwise at 2°C to a mixture of 0.5 g of N-{1- [bis (4-chlorophenyl)methyl]azetidin-3-yl}-N- (3-methoxy- 62 phenyl ) methylsulfonamide in 20 cm3 of dichloromethane . After 20 hours at room temperature, the reaction medium is poured over ice and extracted with 60 cm3 of dichloromethane. The organic phase [lacuna] washed with 3 times 80 cm3. of water and then twice with 80 cm3 of a saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and then evaporated to dryness under reduced pressure (2.7 kPa) . 0.33 g of a white foam is obtained which, is taken up in ■ acetonitrile , filtered and dried in order to obtain 0.20 g of a white solid NMR spectrum (300 MHz, CDC13, δ in ppm) : 2,81 (s : 3H) ; 2.86 (broad t, J = 7.5 Hz : 2H) ; 3.50 (broad t, J = 7.5 Hz : 2H) ; 4.20 (s : 1H) ; 4.53 (mt : 1H) ; 5.36 (unresolved complex : IB); from 6.70 to 6.85 (mt : 3H) from 7.15 to 7.35 (mt : 9H)] .
Example 18 N- ( 1- [Bis ( 4-chlorophenyl) methyl] azetidin-3- yl } -N- ( 3-methoxyphenyl ) methylsulfonamide may be prepared by carrying out the procedure as described in. Example -15, starting with 1.58 g of N-(3-. methoxyphenyl ) methylsulfonamide and 2.0 g of l-[bis(4- chlorophenyl) methyl] azetidin-3-ol . After chromatography on a silica gel column (particle size 0.06-0.04 mm, height 24 cm, diameter 7.8 cm), eluting under an argon pressure of 0.7 bar with an ethyl acetate/cyclohexane 50/50 and then 40/60 by volume mixture and collecting 100-cm3 fractions, fractions 7 to 10 are combined and 63 concentrated to dryness under reduced pressure (2.7, kPa) . (2.05 g) . After crystallization from diisopropyl ether, filtration and drying, 0.21 g of N- ( 1- [bis ( 4 -chlorophenyl) methyl] azetidin-3-yl } -N- ( 3-methoxyphenyl )methylsulfonamide is obtained.
N- ( 3-Methoxyphenyl ) methylsulfonamide may be prepared by carrying "out the procedure in the following manner: 3.14 cm3 of methylsulfonyl chloride are added at 3°C to a mixture of 5.0 g of 3-methoxyaniline in 150 cm3 of. -pyridine . After 20 hours at room temperature, 200 cm3 of water and 400 cm3 of ethyl acetate are added and the reaction medium is separated after settling. The organic phase is washed with 3 times "400 cm3 of water and .400 cm3 of a saturated sodium chloride solution, dried over magnesium sulfate, filtered and then ' evaporated to dryness under reduced pressure (2.7 kPa) . After chromatography on a silica gel column (particle size 0..06-0.04 mm, height 23 cm,, diameter.7.8 cm), eluting under an argon pressure of 0.7· bar with an ethyl acetate/cyclohexane 25/75 by volume mixture and collecting 100-cm3 fractions, fractions 24 to 36 are combined and concentrated to dryness under reduced pressure (2.7 kPa) , 6.21 g of N-(3-methoxyphenyl ) methylsulfonamide are obtained in the form of an orange-colored oil.
Example 19 N- { 1- [Bis ( 4 -chlorophenyl ) methyl ] azetidin-3- ■ yl } -N- ( 3-hydroxymethylphenyl ) methylsulfonamide may be 64 prepared by carrying out the procedure in the following manner: 1.46 cm3 of a 20% toluenic solution of diisopropylaluminum hydride are added dropwise at -50°C to a mixture of 0.5 g of ethyl N- { 1- [bis ( 4-chloro-phenyl) methyl] azetidin-3-yl } -N- (methylsulfonyl) -3-aminobenzoate in 20 cm3 of toluene. After 1.5 hours at 0°C and 1.5 hours at 10°C, the reaction medium is cooled to 0°C and 20 cm3 of water are added slowly.
After filtration of the precipitate and extraction with ethyl acetate, the organic phase is washed with twice 80 cm3 of water and then 80 cm3 of a. saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and then evaporated to dryness under reduced pressure (2.7 kPa) . 0.46 g of an oil is obtained which is chromatographed on a silica gel column (particle size 0.06-0.04 mm, height 16 cm, diameter 4 cm), eluting under an argon pressure of 0.7 bar with an ethyl acetate/cyclohexane 40/60' by volume mixture and collecting 20-cm3 fractions, fractions 72 to 76 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 0.20 g of N- { 1- [bis ( 4'-chlorophenyl ) methyl] azetidin-3-yl } -N- ( 3-hydroxymethylphenyl) methylsulfonamide is obtained in the form of a white solid [XH NMR spectrum. (300 MHz, CDCI3 , δ in ppm) : 1.80 (mt : 1H) ; 2.83 (s : 3H) ; 2.87 (mt : 2H) ; 3.52 (mt : 2H) ; 4,21· (broad s : 1H) ; 4.60 (mt : 1H) ; 4.74 (broad t, J = 4 Hz : 2H) from 7.10 to 7.45 (mt : 12H)]'. 65 Example 20 Ethyl N- { 1- [bis ( 4-chlorophenyl ) methyl] -azetidin-3-yl } -N- (methylsulfonyl ) -3-aminobenzoate may be prepared by carrying out the procedure as described in Example 15,· starting with 1.58 g of ethyl .N- (methylsulfonyl) -3-aminobenzoate and 2.0 g.of l-[bis(4-chlorophenyl) methyl] azetidin-3-ol . After chromatography on a silica gel column (particle size 0.06-0.04 mm, height 24 cm, diameter 7.8 cm), eluting under- an argon pressure of 0.7 bar with an ethyl acetate/cyclohexane' 50/50 and then 40/60 by volume mixture and collecting 100-cm3 fractions, fractions 7 to 10 are combined and concentrated to dryness under reduced pressure (2.7 kPa) to give 2.0 g of a yellow oil.
Ethyl N- (methylsulfonyl ) -3-aminobenzoate may be prepared by carrying out the procedure in the following manner: 2.35 cm3 of methylsulfonyl chloride are added at 3°C to a mixture of 5.0 g of. ethyl. 3-aminobenzoate in 150 cm3 -of pyridine. After 20 hours at room temperature, 200 cm3 of water, and 400 cm3 of ethyl acetate are added and the reaction medium is separated after settling. The organic phase is washed with 3 times 400 cm3 of water and 400 cm3 of a saturated sodium chloride solution, dried over magnesium sulfate, filtered and then evaporated to dryness under reduced pressure (2.7 kPa) . After chromatography on a silica gel column (particle size 0.06-0.04 mm, height 25 cm, diameter 7.8. cm), eluting under an argon pressure of 66 0.7 bar with an ethyl acetate/cyclohexane 25/75 by volume mixture and collecting 100-cm3 fractions, fractions 27 to 36 are combined and concentrated to dryness under reduced pressure (2.7 kPa) , 5.24 g of ethyl N- (methylsulfonyl ) -3-aminobenzoate are obtained in the form of an orange-colored oil.
Example 21 N-{1- [Bis ( 4 -chlorophenyl) methyl] azetidin-3-yl } -N- ( l-isobutylpiperid-4 -yl ) methylsulfonamide may be prepared by carrying out the procedure in the following manner: 0.11 cm3 of isobutyraldehyde , 0.057 cm3 of 100% acetic acid and 320. mg of sodium triacetoxyborohydride are added to a solution of 0.47 g of N-{l-[bis(4-chlorophenyl ) methyl] azetidin-3-yl } -N- ( piperid-4-yl ) methylsulfonamide in 20 cm3 of dichloromethane . After stirring for 20 hours at 20°C, the reaction mixture is supplemented with 50 -cm3 of a saturated aqueous sodium hydrogen carbonate solution and separated after settling. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) ..· The residue is purified by chromatography on . a silica gel' column (particle size 0.063-0.200 mm, height 20 cm, diameter 2 cm), eluting under an argon pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (40/60 by volume) and collecting 30-cm3 fractions. Fractions 3 to 15 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 0.22 g of N- { 1- [bis ( 4-chloro- 67 phenyl ) methyl ] azetidin-3-yl } -N- ( l-isobutylpiperid-4 - yl ) methylsulfonamide is obtained in the form of a white foam [XH NMR spectrum (300 MHz, CDC13, δ in ppm) : 0.87 (d, J = 7 Hz : 6H) ; from 1.60 to 1.90 (mt : 5H) ; 1.93 (broad t, J = 11.5 Hz : 2H) ; 2.03 (d, J = 7.5 Hz : 2H) ; 2.84 (s, 3H) ; 2.89 (broad d, J = 11.5 Hz : 2H) ; 3.38 (broad t, J = 7 Hz : 2H) ; 3.47 (broad t, J = 7 Hz : 2H) ; 3.62 (mt : 1H) ; 4.08 (mt : 1H) ; 4.43 (s : 1H) ; from 7.20 to 7.40 (mt : 8H) ] .
N- { 1- [Bis ( 4-chlorophenyl) methyl] azetidin-3- yl } -N- (piperid-4-yl) methylsul fonamide may be prepared by carrying out the procedure in the following manner: 50 cm3 of a 6 N hydrochloric acid solution in dioxane is poured slowly into a solution of 19 g of N-{l-[bis(4- chlorophenyl) methyl] azetidin-3-yl } -N- ( 1-tert-butoxy- carbonylpiperid-4 -yl ) methylsulfonamide in 100 cm3 of dioxane. After stirring for 20 hours at 20°C, the .reaction mixture is concentrated at 50 °C under reduced pressure. (2.7 kPa) . The residue is taken up in 200 cm3, of. ethyl acetate and in 200 cm3 of water. The aqueous phase is alkalinized with a 4 N aqueous sodium hydroxide solution and then extracted with 200 cm3 'of ' ethyl acetate. This organic phase is dried over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) . 15.5 g of N- { 1- [bis ( 4-chlorophenyl) methyl] azetidin-3-yl } -N- (piperid-4 -yl ) methylsulfonamide are obtained in the ■ form of a cream-colored foam. 68 N- { 1- [Bis ( -chlorophenyl ) methyl] azetidin-3- yl } -N- ( l-tert^butoxycarbonylpiperid-4 -yl ) methyl-• sulfonylamide may be prepared by carrying out the procedure in the following manner: 4.60 cm3 of methyl- sulfonyl chloride are added slowly to · a solution of 14.7 g of 4-{ 1- [bis ( 4 -chlorophenyl ) methyl] azetidin-3- ylamino } - ( 1-tert-butoxycarbonyl )'piperidine in 250 cm3 of dichloromethane followed by 4.60 cm3 of triethylamine and 100 mg of 4-dimethylaminopyridine . After stirring for 20 hours at 20°C, the reaction mixture is supplemented with 200 cm3 , of a saturated aqueous sodium hydrogen carbonate solution and then stirred for 30 minutes and separated after settling. The organic phase is dried over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) . The foam obtained, taken up in 250 cm3 of dichloromethane, is again supplemented slowly with 4.60 cm3 of methylsulfonyl chloride and then with 4.60 cm3 of triethylamine and 100 mg of 4-dimethyl- aminopyridine . After stirring for 20 hours at 20°C, the mixture is supplemented with 200 cm3 of a saturated aqueous sodium hydrogen carbonate solution and then stirred for 30 minutes and separated after settling-. The organic phase is dried over magnesium sulfate, filtered and then concentrated to. dryness under reduced pressure (2.7 kPa) . The residue is purified by chromatography on a silica gel column (particle size 0.063-0.200 mm, height 35 cm, diameter 5 cm), eluting 69 under an argon pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (70/30 by volume) and collecting 250-cm3 fractions. Fractions 4 to 18 are combined and concentrated to dryness under reduced pressure (2.7 JPa) . 19 g of N-{l-[bis(4-chlorophenyl) methyl] azetidin-3-yl } -N- ( 1-tert-butoxycarbonylpiperid- -yl ) methylsulfonylamide are obtained in the form of a . cream-colored foam which will be used as it is in the next step. 4- { 1- [Bis (4-chlorophenyl ) methyl] azetidin-3-ylamino } - ( 1-tert-butoxycarbonyl ) piperidine may be prepared by carrying out the procedure in the following manner: 6.58 g of l-tert-butoxycarbonylpiperidin-4 -one are added to a solution of 9.22 g of 1- [bis (4-chlorophenyl) methyl] azetidin-3-ylamine in 300 cm3 of dichloromethane . 9.54 g of sodium triacetoxyborohydride are added, in two portions, to the mixture, cooled to +5°C, and then 1.72 cm3 of 100% acetic acid are poured in. After stirring for 20 hours at 20°C, the reaction mixture is supplemented slowly with 500 cm3 of a saturated aqueous sodium hydrogen carbonate solution and .then thoroughly stirred and separated after settling. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness at 50°C. under reduced pressure (2.7 kPa) . 15 g of 4-{l-[bis(4-chlorophenyl ) methyl] azetidin-3-ylamino } - (1-tert-butoxycarbonyl ) piperidine are obtained in the form of a 70 cream-colored foam which- will be used as it. is in the. next. step.
Example 22 N-Benzyl-N-{1- [bis (4- chlorophenyl ) methyl] azetidin-3-yl } amine : 0.134 cm3 of benzaldehyde is added, at room temperature under an argon atmosphere, to a solution of 369 mg of l-[bis(4- . chlorophenyl ) methyl] azetidin-3-ylamine in 15 cm3 of dichloromethane. The mixture is cooled to around 0°C, before gradually adding thereto 382 mg of sodium triacetoxyborohydride , and then 70 mm3 of acetic acid. After stirring for 16 hours at room temperature, the mixture is poured over 50 cm3 of a saturated aqueous sodium hydrogen carbonate solution and then extracted with twice 25 cm3 of dichloromethane. The combined organic phases are dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) . The residue obtained is purified by flash chromatography on silica gel [eluent:- dichloromethane/methanol (95/5 by volume)]. 0.29 g of N.-benzyl-N- { 1- [bis ( 4 -chlorophenyl ) methyl] azetidin-3-■ yl } amine is obtained in the form of a colorless oil [1H NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.71 (broad t, J = 7. Hz : '2H); 3.42 (mt -: 2H) ; 3.49 (mt : 1H) ; 3.70 (s .: 2H) ; 4.25 (s : 1H) ; from 7.20 to 7.40 (mt : 13H) ] . 1- [Bis (4-chlorophenyl)methyl] azetidin-3- ylamine may be obtained in the following manner: 400 cm3 of a mixture of methanol and liquid ammonia (50/50 by 71 volume) are added to 27 g of 1- [bis ( 4 -chlorophenyl ) - methyl] azetidin-3-yl methylsulfonate . contained in an autoclave previously cooled to around -60 °C. The reaction medium is then stirred at 60°C for 24 hours . and then abandoned in the open air in order to allow the evaporation of the ammonia and finally concentrated under reduced pressure (2.7 kPa) . The residue is taken up in 500 cm3 of' a 0.37 N aqueous sodium hydroxide solution and extracted with four times 500 cm3 of ethyl ether. The combined organic phases are washed successively with twice 100 cm3 of distilled water and 100 cm3 of a saturated sodium chloride solution, dried over magnesium sulfate, filtered, and concentrated under reduced pressure (2.7 kPa) . The residue obtained is purified by flash chromatography on silica gel [eluent: dichloromethane/methanol (95/5 by volume)]. 14.2 g of l-.[bis ( 4 -chlorophenyl) methyl] azetidin-3-ylamine are obtained in the form of an oil which solidifies into a cream-colored solid.
Example 23 N-Benzyl-N-{1- [bis (4- chlorophenyl ) methyl] azetidin-3-yl } methyl sulfonamide : 104 mm3 of triethylamine are added, at room temperature under an argon atmosphere, to a solution of 120^ mg of N-benzyl-N- { 1- [bis ( 4 -chlorophenyl ) methyl ]azetidin-3- yl } amine in 5 cm3 of dichloromethane . The mixture is cooled to around 0°C before adding thereto 46.4 mm3 of ' methylsulfonyl chloride, and then it is stirred at room 72 temperature for 16 hours. The reaction mixture, is diluted with 20 cm3 of dichloromethane and then is washed with twice 15 cm3 of distilled water. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) , providing .a lacquer which is crystallized by trituration in methanol. 42 mg of N-benzyl-N- { 1- [bis ( 4 -chlorophenyl ) methyl] azetidin-3-yl } methylsulfonamide are thus obtained in the form of a cream-colored powder melting at 171°C.
Example 2 N- { 1- [Bis ( 4 -chlorophenyl ) methyl ] azetidin-3-yl } -N- ( 3 , 5-difluorobenzyl ) amine may be prepared as in Example 22, but using 188 mg of 3 , 5-difluoro-benzaldehyde and 369 mg of 1- [bis .( 4 -chlorophenyl ) -methyl ] azetidin-3-ylamine and 382 mg .of sodium triacetoxyborohydride, without purification by flash chromatography. 0.48 g of N- { 1- [bis ( 4 -chlorophenyl ) -methyl ] azetidin-3-yl } -N- ( 3 , 5-difluorobenzyl ) amine is obtained in the form of a colorless oil [XH NMR spectrum (300 MHz , CDC13, δ in ppm) : 2.73 (mt : 2H) ; from 3.40 to 3.55 (mt : 3H) ; 3.70 (s : 2H) ; 4.26 (s : 1H) ; 6.69 (tt, . J = 9 and 2 Hz : 1H) ; 6.83 (mt : 2H) ; from 7.20 to 7.35 (mt. : 8H) ] .
Example 25 N-{ 1- [Bis (4 -chlorophenyl) methyl ] azetidin- 3-yl } -N- ( 3 , 5-difluorobenzyl) methylsulfonamide s 73 347 mm3 of triethylarnine are added, at room temperature under an argon atmosphere, to a solution of 433 mg of N- ( 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3-yl } -N- ( 3 , 5-difluorobenzyl ) amine · in 30 cm3 of dichloro-methane. The mixture is cooled to around 0°C before adding thereto a solution of 46.4 mm3 of methylsulfonyl •chloride in 5 cm3 -of dichloromethane , and then it is stirred' at room temperature for 1 hour. The reaction mixture is diluted with 20 cm3 of dichloromethane and is then washed with twice 20 cm3 of distilled water. The organic phase is dried over magnesium, sulfate, filtered and concentrated - to. dryness under reduced pressure (2.7 kPa) . The residue is introduced into solution in methanol on a Bond. Elut® SCX cartridge (10 g) , eluting successively with methanol and with a .1 M. solution of ammonia in methanol. The ammoniacal fractions are pooled and concentrated to dryness under reduced pressure (2.7 kPa) ..· 0.44 g of N- { 1- [bis ( -chloro-phenyl ) methyl ] azetidin-3-yl } -N- (3, 5-di.fluorobenzyl ) -methylsulfonamide is thus obtained in the form of a cream-colored foam [XH N R spectrum (300 MHz, CDC13, δ in ppm) : 2.81 (s : 3H) ; 3.02 (broad t, J .= 7.5 Hz : 2H) ; 3.38 (broad t, J = 7.5 Hz : 2H) ; 4.23 (s : 1H) ; 4.40 (mt :. 1H) ; 4.54 (s : 2H) ; 6.75 (tt, J = 9. and 2 Hz : 1H)..; 6.95 (mt : .2H) ; 7.25 (mt : 8H) ] .
Example 26 N- { 1- [Bis (.4 -chlorophenyl ) methyl] azetidin-3-yl } -N- ( 3 , 5-difluorobenz l ) acetamide 74 1.6 cm3 of triethylamine are added,- at room temperature under an argon atmosphere, to a solution of 2 g of- N- { 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3-yl } -■ N- ( 3 , 5-difluorobenzyl ) amine in 75 cm3 of dichloro- methane. The mixture is cooled to around 0°C before adding dropwise. thereto 0.66 cm3 of acetyl chloride, and then it is stirred at room temperature for 16' hours. The reaction mixture is diluted with 50 cm3 of dichloromethane and is then washed with twice 20 cm3 of distilled water. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). The residue .obtained is purified by flash chromatography on silica gel [eluent: dichloromethane/methanol (98/2 by volume)]. 1.2 g of N- { 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3- yl } -N- ( 3 , 5-difluorobenzyl ) acetamide are obtained in the form of a colorless oil [1H NMR spectrum (300 MHz, CDCI3, δ in ppm) . A mixture of rotame.rs is observed. * 2.06 and 2.14 (2s : 3H in total); 2.97 (mt : 2H) ; 3.43 (mt : 2H); 4.20 and 4.25 (2s : 1H in total); 4.54 and from 4.75 to 4.80 (mt : 1H in total); 4.68. and 4.78 (broad 2s : 2H in total); 6.70 (mt : 3H); 7.24 (broad s : 8H) ] .
Example 27 N- { 1- [Bis (4 -chlorophenyl).methyl] azetidin-3- yl } -N- ( pyrid- -ylmethyl) methylsulfonamide ■ 346 mm3 of triethylamine are added, at room temperature under an argon atmosphere, to a solution of 75 398 mg of N- { 1- ['bis ( 4-chlorophenyl) methyl ] azetidin-3-yl } -N- (pyrid-4-ylmethyl ) amine in 8 cm3 of dichloromethane . The mixture is cooled to around 0°0'· before adding thereto 155 mm3 of methylsulfon l choride, and then it is stirred at room temperature for -3 hours. The reaction mixture is diluted with 35 cm3 of. dichloromethane and is then washed with twice 20 cm3 of distilled water. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7. kPa)".. The residue obtained is purified. by flash chromatography on silica gel [ eluent : dichloromethane/methanol ('97/3 by volume)]. 288 mg of N- { 1- [bis.( 4-chlorophenyl ) methyl ] azetidin-3-yl } -N- (pyrid-4-ylmethyl ) methylsulfonamide are obtained in the form of a cream-colored foam [1H NMR spectrum (300 MHz , CDC13, 5 in ppm) : .2.83 (s : 3H) ; 3.02 (broad . t, J = 7.5 Hz : 2H) ; 3.40 (broad t, J = 7.5 Hz : 2H) ; 4.23 (s : 1H); 4.43 (mt : 1H) ; 4.57 (s.: 2H) ; from 7.20 to 7.35 (mt : 8H) ; 7.32 (broad d, J = 5.5 Hz .: 2H) ; 8.60 (broad d, J = 5.5 Hz : 2H) ] .
Example 28 N- { 1- [Bis (4-chlorophenyl ) methyl ] azetidin-3--yl } -N- (pyrid-4-ylmethyl ) amine may be prepared in the following- manner: 0.126 cm3 of pyrid-4 -ylcarboxaldehyde is added, at room temperature under an argon' atmosphere, to a solution of 369 mg of l-[bis(4-chlorophenyl ) methyl] azetidin-3-ylamine in 15 cm3 of dichloromethane. The mixture is cooled to around 0°C, 76 before gradually adding thereto 382 mg of sodium triacetoxyborohydride, and then 70 mm3 of acetic acid. , After stirring for 72 hours at room temperature, the mixture is poured over 100 cm3. of a saturated aqueous sodium hydrogen carbonate solution and then extracted with twice 100 cm3 of dichloromethane . The combined organic phases are washed with 50 cm3 of distilled water, dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure {2. kPa) . The residue is introduced into solution in 5 cm3 of methanol on a Bond Elut® SCX cartridge (10 g) , eluting · successively with 50 cm3 of methanol, and with 60 cm3 of a 1 M solution of ammonia in methanol. The ammoniacal fractions are pooled and concentrated to . dryness under reduced pressure (2^7. kPa) . 0.48 g of N- { 1- [bis ( 4-chlorophenyl ) methyl] azetidin-3-yl}-N- . (pyrid-4 -ylmethyl) amine is thus obtained in the form. of a colorless oil .
Example 29 N- { 1- [Bis ( 4-chlorophenyl ) methyl ] azetidin-3- yl}-N- (pyrid-3-ylmethyl ) methylsulfonamide By carrying out the operation according to.' the procedure of Example 27, but' starting with 380 mg of N- { 1- [bis (4-chlorophenyl ) methyl ]azetidin-3-yl} -N- (pyrid-3-ylmethyl) amine, 319 mg of N- { 1- [bis ( 4 -chloro- phenyDmethyl] azetidin-3-yl } -N- (pyrid-3-ylmethyl) - methylsulfonamide are obtained in the form of a cream- colored foam [lH NMR spectrum (300 MHz, CDC13, 5 in 77 ppm) : 2.80 (s : 3H) ; 3.02 (split t, J' = 7 and 1.5 .Hz : 2H) ;. 3.38 (split t, J = 7 and 1.5' Hz : 2H) ; 4:22 (s ": 1H) 4.3-5. (mt : 1H) ;■ 4.56 (s : 2H) ; 7.23 (broad s : 8Ή) ; 7.31 (dd, J = 8 and 5 Hz : 1H); "7.80 (broad d, J = 8 Hz : 1H).; 8.57 (dd, J = 5 and 1.5 Hz ': 1H) ; 8.63 (broad d, J = 1.5 Hz : 1H)] .
Example 30 N-{1- [Bis (4-chlorophenyl)methyl] azetidin-3- yl } -N- (pyrid-3-ylmethyl ) amine may be prepared as in Example 28, but starting with 0.124 cm3 of pyrid-3- ylcarboxaldehyde, 0.36 g of 1- [bis ( -chlorophenyl ) - methyl ] azetidin-3-ylamine and 0.38 g of sodium triacetoxyborohydride . 0.44 g of N- { 1- [bis ( 4-chloro-• phenyl ) methyl] azetidin-3-yl } -N- (pyrid-3-ylmethyl ) amine is "thus obtained in the form of a colorless oil.
Example 31 N- { 1- [Bis (4 -chlorophenyl ) methyl] azetidin-3- yl}-N- (1, l-dioxo-lH-l 6-benzo [d] isothiazol-3-yl )' amine 182 mg of 1 , 2-benzisothiazol-3-amine 1,1-, dioxide and 326 mg of cesium carbonate are added to 386 mg of 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3-yl methylsulfonate in solution in 10 cm3 of dimethyl- formamide. The reaction medium is then stirred at 100°C ' for 9 hours and then concentrated under reduced pressure (2.7 kPa) . The residue is washed four times with 5 cm3 of boiling distilled water, disintegrated by stirring in 5 cm3 of distilled water at room temperature and then recovered by filtration and purified by flash 78 chromatography on silica gel' [eluent: dichloro- methane/methartol (98/2 by volume)]. 53 mg of N-{1- [bis ( 4 -chlorophenyl ) methyl] azetidin-3-yl } -N- ( 1 , 1-dioxo- lH-lλ6-benzo [d] isothiazol-3-yl ) amine are obtained in the form of a pasty product [ [XH NMR spectrum (300 MHz , CDCI3, δ in ppm) : 3.17 (mt :. 2H); 3.61 (broad t, J = 7.5 Hz : 2H) ; 4.37 (s : 1H) ; 4.75 (mt : 1H) ; from 6.30 to 6.40 (unresolved complex : 1H) ; from 7.20 to 7.35 (mt : 8H) ; 7.62 (broad d, J = 7.5 Hz : 1H) ; 7.69 (broad t, J = 7.5 Hz : 1H) ; 7.76 (broad .t, J = 7.5 Hz : 1H) ; 7.93 (broad d, J = 7.5 Hz : 1H) ] . 1, 2-Benzisothiazol-3-amine 1,1-dioxide may be prepared according to the method described by Stoss, P. et al., Chem. Ber. ( 1975 ) , 108 ( 12 ) , 3855-63. · Example 32 N- { 1- [Bis (4 -chlorophenyl) methyl] azetidin- 3-: yl } -N- ( 3 , 5-di fluorophenyl ) -N' -tert-butyloxycarbonyl- . sulfamide may be prepared in the . following manner: 0..048 cm3 of chlorosulfonyl isocyanate. is added to- a solution of 0.095 cm3 of tert-butyl alcohol in 2 cm3 of anhydrous dichloromethane, and after stirring for 2 minutes 0.21' g of' { 1- [bis ( 4-chlorophenyl ) methyl ] - azetidin-3-yl } - ( 3 , 5-difluorophenyl ) amine in 1.25 cm3 of anhydrous dichloromethane and then 0.084 cm3 of triethylamine are successively added. After stirring for 1 hour at a temperature in the region of 20°C, 2 cm3 of a saturated sodium bicarbonate solution are added with vigorous stirring. The reaction medium is 79 separated after settling, dried over magnesium sulfate, filtered and then concentrated . to dryness under reduced' pressure (2.7 kPa) . The residue obtained is chromatographed on a Varian cartridge (6 cm3) filled with 3 g of fine silica (0.040-0.063 mm), conditioned and then eluted with a petroleum ether-ethyl acetate mixture with the. aid of a Duramat 'pump, collecting 2-cm3 fractions. Fractions 6 to 17 are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 40°C for 2 hours. 61 mg of N-{l-[bis(4-chlorophenyl ) methyl] azetidin-3-yl } -N- (3, 5-difluorophenyl ) -N' -tert-butyloxycarbonylsulfamide are thus obtained in the form of a white foam [1H NMR spectrum (400:MHz, CDC13, δ in ppm) : 1.47 (s .: 9H) ; 2.77 (broad t, J = 8 Hz : 2H) ; 3.52 (mt : 2H) ; 4.19 (s : 1H) ; 5.06 (mt : 1H) ; from 6.75 to 6.90 (mt :; 3H) ; from 7.15 to 7.35 (mt : 8H] .
Example 33 (RS) -N-{ 1- [ (4-Chlorophenyl) yridin-3-ylmethyl ] azetidin-3-yl } -N- ( 3 , 5-difluorophenyl ).methyl-sulfonamide may be obtained in the following manner: 0.2 g of potassium carbonate and 23 mg of .potassium iodide are added to a mixture of 0.2 g of 3- [bromo- ( 4-chlorophenyl ) methyl ] pyridine and 0:22 g of N-azetidin-3-yl-N- (3, 5-difluorophenyl) methylsulfonamide hydrochloride in 10 cm3 of acetonitrile , and then the mixture is- heated under reflux for 3 hours. After adding 0.2 g of potassium carbonate, the mixture is heated under 80 reflux for an additional 15 hours. After cooling to. 21°C, the insoluble materials are removed by filtration and then the filtrate is concentrated to dryness at 40°C under 2.7 kPa . 170 mg of a colorless lacquer are obtained, which lacquer is purified by. chromatography on a silica cartridge (reference SIL-020-005, FlashPack, Jones Chromatography Limited, New Road, Hengoed, Mid Glamorgan, CF82 8AU, United Kingdom) eluting with a cyclohexane : ethyl acetate 1:1 mixture (6.cm3/min, 5-cm3 fractions) . The fractions with an Rf=5/57 ( cyclohexane : ethyl acetate 1:1, silica plate,. Merck reference 1.05719, Merck KGaA, 64271 Darmstatd, ■ Germany) are combined and concentrated under 2.7 kPa at 40°C to give 100 mg of (RS ) -N- { 1- [ ( -chlorophenyl ) -pyridin-3-ylmethyl] azetidin-3-yl } -N- ( 3 , 5-difluorophenyl ) methylsulfonamide melting at-110°C .[1H NMR spectrum (300 MHz, (CD3)2SO d6, δ in ppm): 2.77 (mt :■ 2H) 2.98.(s : 3H) ; 3.38 (mt : 2H) ; 4.50 (s : IH); 4.70 (mt : 1H); 7.11 (mt : 2H) ; f om.7.20. to. 7.40 (mt : 2H) ; 7.34 (d, J = 8 Hz : 2H) ; 7.41 (d, J= 8 Hz : 2H) ; 7.72 (broad d, J = .8 Hz : 1H) ; 8.40 (dd, J = 5 and 1.5 Hz : 1H) ; 8.58 (dr J = 1.5 Hz : 1H) ] . ■ The two isomers of (RS).-N-(l-[ ( 4 -chlorophenyl ) pyridin-3-ylmethyl ] azetidin-3-yl } -N- ( 3 , 5-difluorophenyl ) methanesulfonamide may be separated on a CHIRACEL OD chiral stationary phase.
First isomer: lti NMR- spectrum (300 MHz, CDC13, δ in ppm) : 2.82 (s : 3H); 2.87 (mt : 2H) ; 3.53 (mt : 81 2H) ; 4.29 (s.Y lH); 4.47 (mt : 1H) ; 6.80 (mt . : 3H) ; 7.19. (dd, J = 8 and 5 Hz : 1H) ; from 7.20 to 7.35 (mt : 4H) ; 7.62 (broad d, J = 8 Hz : 1H) ; 8.45' (broad d, J = 5 Hz : 1H) ; 8.59 (broad s : 1H) .
Second isomer: 1H NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.82 (s : 3H) 2.87 (mt : 2H) ; 3.54 (mt : 2H) ; 4.29 (s : 1H) ; 4.48 (mt : 1H) ; 6.80 (mt : 3H) ; 7.19 (broad dd, J = 8 and 5 Hz : 1H) ; from 7.25 to 7.35 (mt : 4H) ; 7.62 (dt, J = 8 and 2 Hz : .1H) ; 8.46 (dd, J = 5 and 2 Hz : 1H) ; 8.59 (broad d, J = 2 Hz : 1H) .
N-Azetidin-3-yl-N- (3 , 5-difluorophenyl) methyl-sulfonamide hydrochloride is obtained in the following manner: in a 500-cm3 hydrogenator, a solution of 1 g of N- (l-benzhydrylazetidin-3-yl) -N- (3, 5-difluorophenyl) -methylsulfonamide in a mixture of 2.5 cm3 of 1M hydrochloric acid and 0.41 cm3 of acetic acid is hydrogenated in the presence of, 0.161 g of palladium hydroxide at a hydrogen pressure of 30 bar for 4 hours. The catalyst is removed by filtration on a celite bed and then the filtrate is concentrated to dryness at 40°C under 2.7 kPa to give 630 mg of N-azetidin-3-yl-N-(3, 5-difluorophenyl) methylsulfonamide, melting at 216°C N- (l-Benzhydrylazetidin-3-yl) -N- (3, 5-difluorophenyl) methylsulfonamide may be obtained by carrying out the procedure as in Example 13 -^(method 2) in the following manner: 0.86 g of N- (3, 5-difluoro- 82 phenyl ) methylsulfonamide , 3.28 g of triphenylphosphine-and .then 2 ml of diethyl azodicarboxylate are added successively to a solution of 2 g of 1-benzhydryl- -azetidin-3-ol in 100 cm3 of tetrahydrofuran . An increase in the temperature, which passes from 22°C to 29°C, as well as the formation of a precipitate immediately, following the addition of the diethyl azodicarboxylate are observed. After 20 h at 22°C, the precipitate is removed by filtration and the filtrate is concentrated to., dryness at 40°C under 2.7 kPa . The residue is triturated with 5 cm3 of methanol for 20 minutes at 21CC, providing 1.07 g of N- ( l-benzhydrylazetidin-3-yl ) -N- ( 3 , 5-difluorophenyl ) methylsulfonamide in the form of a white amorphous solid. l-Benzhydrylazetidin-3-ol may be prepared according to the procedure described by KATRITZKY A.R. et al., J. Heterocycl. Chem. , 271 (1994). 3- [Bromo ( 4-chlorophenyl ) methyl] pyridine is obtained in the following manner: 3.5..cm3 of a 48% solution of hydrobromic acid in acetic acid and 1 cm3 of acetyl bromide are added to 1.5 g of (4-chlorophenyl)-pyridin-3-ylmethanol . The amber-colored mixture thus obtained is heated under reflux,- for 4 hours and then cooled to 20°C, concentrated to dryness at 40°C under 2.7 kPa, giving 1.53 g of 3- [bromo ( -chlorophenyl ) -methyl] pyridine (Rf=75/90, 254 ran, Silica Plates , reference 1.05719, Merck KGaA, 64271 Darmstatd, Germany) . 83 4- (Chlorophenyl) pyridin-3-ylmethanol is obtained in the following manner: 20 cm3 of a molar solution of 4-chlorophenylmagnesium bromide in ethyl ether are added to a solution of 3 g of 3-pyridine-carboxaldehyde in tetrahydrofuran at 5°C. After heating to 20°C, the mixture is allowed to react for 15 hours, with stirring. 20 cm3 of a saturated ammonium chloride solution are then added, followed by 20 cm3 of ethyl acetate. The mixture is separated after settling and the organic phases are -extracted with an additional 20 cm3 of ethyl acetate. The organic extracts are combined, dried over magnesium sulfate and then concentrated to dryness at 40°C under 2.7 kPa . The residue obtained is chromatographed on silica (Amicon, 20-45 μπι, 500 g silica, column diameter 5 cm) , eluting with a cyclohexane : ethyl acetate mixture from 80:20 to 50:50 under an argon pressure of 0.4 bar. The fractions containing the compound with an Rf=13/53 (Merck Silica -Plates, reference 1.05719, Merck KGaA,. 64271 Darmstatd, Germany) are combined and evaporated to dryness at 40°C under 2.7 kPa to give 2.53 g of 4 -chlorophenyl ) pyridin-3-ylmethanol .
Example 3 N- { 1- [Bis ( 4 -fluorophenyl ) methyl ] azetidin-3-yl } -N- ( 3 , 5-difluorophenyl ) methylsulfonamide is obtained in the following manner: 0.36 g of potassium carbonate and 27 mg of potassium iodide are added to a mixture of 0.2 g of 4 , 4 ' -difluorobenzhydryl chloride and 0.26 g of 84 N-azetIdin-3-yl-N- (3, 5-difluorophenylj - hydrochloride in 1.0 cm3 of a'cetonitrile and then the mixture is heated under reflux for 3 hours-. After cooling to 21° C, the insoluble materials are removed by filtration and then ..the filtrate is concentrated to dryness at 40°C under 2.7 kPa. The residue is triturated with 30 cm3 of ethyl acetate and then the solid is removed by filtration. The filtrate is · concentrated to dryness at 40°C under 2.7 kPa and 90 mg of a pale yellow solid are obtained, which solid is purified by chromatography on BondElut SCX cartridge containing 2 g of graft silica (reference 1225-6019, Varian Associates, Inc. 24201 Frampton Avenue, Harbor City, CA90710, USA) eluting with a 2 M' solution of methanolic aqueous ammonia. The fractions with an Rf=16/82 ( cyclohexane : ethyl acetate 7:3, silica plate, reference 1.05719, Merck KGaA, 64271 Darmstatd, Germany) are combined and concentrated under 2.7 kPa at 40°C to give 243 mg of N- { 1- [bis ( 4-fluorophenyl ) - methyl ] a zetldin-3-yl } -N- ( 3 , 5-difluorophenyl ) methyl- sulfonamide melting at 98°C [¾ NMR spectrum (300 MHz, (CD3)2SO d6, δ in ppm) : 2.74 (broad t, J = 7 Hz : 2H); - 3.00 (s : 3H); 3.37 (broad t, J = 7 Hz : 2K) ; 4.43 (s : 4.69 (mt : 1H) ; from 7.05 -to.7.20 (mt : 6H) ; 7.28 (tt, J = 9 and 2.5 Hz :■ 1H).; 7.40 (mt : ' 4H) ] .
Example 35 (RS) -N-{ 1- [ ( 4-Chlorophenyl) pyridin-4- ylmethyl],azeti.din-3-yl ) -N- ( 3, 5-difluorophenyl ) methyl- sulfonamide may be obtained in the following manner: a 85 mixture of about 10G mg of . ( 4-pyridyl ) ( 4 -chlorophenyl ) - chloromethane ,' 143 mg of N-azetidin-3-yl-N- ( 3 , 5- difluorophenyl ) rnethylsulfonamide hydrochloride, - 17 mg of potassium iodide and 200 mg of potassium carbonate in 5 cm3 of acetonitrile is stirred for about 18 hours at a temperature in the region of 20°C..The reaction ' mixture is then heated under reflux for 3 hours, supplemented with 17 mg o'f potassium iodide and kept under reflux for an additional 2 hours. After cooling to-,a temperature in the region of 20°C, the reaction medium is filtered on sintered glass. The solid is rinsed with acetonitrile and then with' twice 3 cm3 of ethyl acetate. The filtrates are concentrated to dryness under reduced pressure. 230 mg of a pale yellow paste are obtained, which paste is purified by preparative thin-layer chromatography on silica [4 Merck Kieselgel 60F254 preparative plates; 20x20 cm; thickness 0.5 mm], eluting with a methanol- dichloromethane (5-95 by volume) mixture. After elution of the zone corresponding to the desired product, . filtration on sintered glass and then evaporation of the solvents under reduced pressure at a temperature in the region . of 40°C, 12 mg of (RS) -N- { 1- [ (4- chlorophenyl ) pyridin-4 -ylmethyl ] azetidin-3-yl}-N-.(3,5- difluorophenyl ) methylsulfonamide are obtained [XH NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.82 (s : 3H) ; 2.96 (unresolved complex : 2H) ; from 3.50 to 3.80 (mt : 2H) ; 4.33 (unresolved' complex : IK); 4.54 (mt : 1H) ; 6.82 86 (mt ■: 3H) ; from 7.20 to 7.45 (mt : 6H) ; 8.53 (broad d, J = 5.5 Hz : 2H) ] .
The two isomers of (RS)-N-(l- [ (4-chlorophenyl) pyridin-4-ylmethyl] azetidin-3-yl } -N- (3, 5-difluorophenyl) methanesulfonamide may be separated on a CHIRACEL QJ chiral stationary phase.
First isomer: 1H NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.83 (s : 3H) ; 2.87 (broad t, J = 7.5 Hz : 2H.) ; 3.51 (mt : 1H) / 3.60 (mt : 1H) ; 4.24 (s : 1H) ; 4.50 (mt : 1H) ; 6.82 (mt : 3H) / from 7.20 to 7.35 (mt : 6H) ; 8.50 (broad d, J = 5.5 Hz : 2H) .
Second isomer: 1ti NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.83 (s : 3H) ; 2.88 (t, J = 7.5 Hz : 2H);- 3.51 (mt : 1H) ; 3.61 (mt : .1H) ; 4.25 (s : 1H) ; 4.51 (mt : 1H) ; 6.81 (mt : 3H) ; from 7.20 to 7.35 (mt : 6H); 8.50 (broad d, J = 5.5 Hz : 2H) . (4-Pyridyl) (4-chlorophenyl) chloromethane may be prepared in the following manner: 0.0598 cm3 of thionyl choride- is added to a suspension of 100 mg of (4-pyridyl) (4-chlorophenyl) methanol in 2 cm3 of toluene, cooled to a temperature in the region of 0°C. After 2 hours at a temperature in the region of 0°C and 1 hour at a temperature in the region of 20°C, the reaction medium is concentrated under reduced pressure. About 100 mg of ( -pyridyl ) ( 4-chlorophenyl ) chloromethane are obtained in the form of a white solid. (4-Pyridyl) (4-chlorophenyl) methanol may be prepared in the following manner: 348 mg of sodium 87 tetraborohydride are added, at a temperature in- the regi.on of 20°C, to a solution of 2 g of 4-(4-chloro-benzoyl ) pyridine in 160 cm3 of ethanol. After stirring for 2 hours at a temperature ■ in the region of 20°C, 90 mg of sodium tetraborohydride are added. After about 1.5 hours at the same temperature, the reaction medium is diluted with 200 cm3 of dichloromethane and 200 cm3 of water. The pH of the aqueous phase is adjusted to a value of about 5 by addition of about 13 cm3 of a 1 N aqueous hydrochloric acid solution. After decantation, the aqueous phase is extracted with 3 times 100 cm3 of dichloromethane ., The organic phases are combined, dried over magnesium sulfate, filtered and concentrated under reduced pressure . 2 g of (4-pyridyl) ( -chlorophenyl ) -methanol are thus obtained in the form of a white powder . 88 Example 36 24.4 mg of a 75% dispersion of sodium hydride in' mineral oil are. added, at room temperature under an argon atmosphere, to a solution of 330 mg of {l-[bis(4-chlorophenyl) methyl] azetidin-3-yl } ( 3 , 5-difluoro-benzyl) amine in 25 cm3 of tetrahydrofuran . The mixture is stirred at room temperature for 1 hour before adding thereto 59 mm3 of methyl chloroformate , and then the stirring is maintained for 18 hours under the same ■ conditions. The reaction mixture is supplemented with 0.3 cm3 of distilled water and the tetrahydrofuran is expelled in a rotary evaporator. The residue obtained is extracted with dichloromethane, the organic phase is dried. over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). The residue obtained is purified by flash chromatography on silica gel [eluent: dichloromethane/methanol (97.5/2.5 by volume)]. 328. mg of methyl { 1- [bis ( 4 -chlorophenyl ) -methyl] azetidin-3-yl }-( 3 , 5-difluorobenzyl ) carbamate are obtained in the form of a colorless oil [ΧΗ NMR- spectrum (300 MHz, CDC13, δ in ppm) : 2.97 (mt : 2H) ; 3.39 (mt : 2H) ; 3.71 (s : 3H) ; 4.24 (broad s : 1H); 4.45. (unresolved complex : 1H) ; 4.57 (s : 2H); from 6.65 to 6.80 (mt : 3H) from 7.15 to 7.30 (mt : 8H) ] .
Example 37 (RS) -N- ( 1- [ ( 4 -chlorophenyl ) pyrimidin-5-ylmethyl ] azetidin-3-yl } -N- ( 3 , 5-difluorophenyl ) -methylsulfonamide may be obtained by - carrying out the 89 procedure as in Example 33, starting with 0.16. g of (RS) -5- [bromo- ( 4-chlorophenyl ) methyl ] pyrimidine hydrobromide, 0.131 g of N-azetidin-3-yl- N- (3, 5-difluorophenyl) methanesulfonamide hydrochloride in 5 cm3 of acetonitrile, 303 mg of potassium carbonate • and 95 mg of potassium iodide; 26 mg of (RS)-N-{1- [ (4-chlorophenyl) pyrimidin-5-ylmethyl ] azetidin-3-yl } - N- (3, 5-difluorophenyl) methylsulfonamide are thus obtained in the form of a yellow foam NMR spectrum (400 MHz-, CDC13, δ in ppm) : 2.83 (s : 3H) ; 2.91 (mt : 2H) ; 3.57 (mt : 2H) ; 4.31 (s : 1H) ; 4.50 (mt : 1H) ; from 6.75 to 6.90 (mt : 3H) ; 7.29- (s : 4H) ; 8.71 (s : 2H) ; 9.08 (s : 1H) ] .
The medicaments according to the invention consist of at least one compound of formula (I) or an isomer or a salt of such a compound, in the pure state or in the form of a composition in which it is combined with any other pharmaceutically compatible product which may be inert or physiologically active. The medicaments according to the invention may be used orally, parenterally, rectally or topically.
As solid compositions for oral administration, tablets, pills, powders (gelatine capsules, sachets) or granules may be used. In these compositions, the active ingredient according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose-;-or silica, under an argon stream. These compositions may also 90 comprise substances- other than diluents, for, example one or more lubricants such as magnesium stearate or talc, a coloring, a coating (sugar-coated tablet) or a glaze.
As liquid compositions for oral administration, there may be used pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or' paraffin oil .
These compositions may comprise substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
Sterile compositions for parenteral administration may be preferably solutions which are aqueous or nonaqueous, suspensions or emulsions. As solvent or vehicle, there may. be used water, propylene glycol, polyethylene glycol, vegetable oils, in . particular' olive oil , in ectable organic esters, for example ethyl oleate or other suitable organic ' solvents. These compositions may also contain adjuvants, in particular wetting, isotonizing, emulsifying, dispersing and stabilizing agents.
Sterilization may be carried out in several ways, for example by asepticizing filtration, by incorporating sterilizing agents into the' composition, by irradiation or by heating. They may also be prepared in the form of sterile solid compositions which may be dissolved at 91 the time of use in sterile water or, any other injectable sterile medium.
Compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cocoa butter, semisynthetic glycerides or polyethylene glycols.
Compositions for topical administration may be, for example,' creams, lotions, collyria, collutoria, nasal drops or aerosols.
In human therapy, the compounds according to the invention are' particularly useful for the treatment and/or prevention of psychoses including schizophrenia, anxiety disorders, depression, epilepsy, neurodegeneration, cerebellar and spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheral neuropathies, glaucomas, migraine, Parkinson's disease, Alzheimer's disease, Huntington's chorea, Raynaud's syndrome, tremor, obsess ve-compulsive disorder, senile dementia, thymic disorders, Tourette ' s syndrome, tardive dyskinesia, bipolar disorders, cancers, movement disorders induced by medicaments, dystonia, endotoxemic shocks, hemorrhagic shocks, hypotension, insomnia, immunological diseases, multiple sclerosis, vomiting, asthma, appetite disorders (bulimia, anorexia) , obesity, memory disorders, intestinal transit disorders, in weaning from chronic treatments and alcohol or drug abuse 92 (opioids, barbiturates, cannabis, cocaine, amphetamine, phencyclide, hallucinogens, benzodiazepines for example) , as analgesics or potentiators of the analgesic activity of the narcotic and nonnarcotic drugs.
The doses depend on the desired effect, the duration of the treatment and the route of administration used; they are generally between 5 mg and 1000 mg per day orally for an adult with unit doses ranging from 1 mg to.250 mg of active substance." In general, the doctor will determine the appropriate dosage depending on the age,. weight and any other factors specific to the subject to' be treated.
The following examples illustrate the compositions according to the invention: EXAMPLE A . Gelatin capsules containing a dose of '50 mg of active product and having the following composition are prepared according to the usual technique: - Compound of formula (I) 50 mg - Cellulose 18 mg - Lactose 55 mg '- Colloidal silica 1 rag - Sodium carboxymethylstarch 10 mg - Talc 10 mg - Magnesium stearate 1 mg 93 EXAMPLE B Tablets containing a dose' of 50 mg of active product and having the following composition are · prepared according to the usual technique: - Compound of formula (I) 50 mg - Lactose . 104 mg - Cellulose .... 40 mg - Polyvidone ' 10 mg - Sodium carboxymethylstarch 22 mg - Talc 10 mg - Magnesium stearate 2 mg - Colloidal silica . 2 mg - Mixture of hydroxymethylcellulose, glycerin, titanium oxide (72-3.5-24.5) qs 1 finished film- coated tablet containing 245 mg EXAMPLE C An injectable solution containing 10 mg of "active product and.- having the following composition is prepared: - Compound of formula (I) 10 mg - Benzoic acid 80 mg - Benzyl alcohol .... 0.06 ml - Sodium benzoate 80 mg - Ethanol, 95% .... · 0.4 ml - Sodium hydroxide 24 mg - Propylene glycol 1.6 ml -■ Water qs 4 ml Material which is outside the scope of the claims does not constitute a part of the claimed invention.

Claims (9)

1. A pharmaceutical composition containing as active ingredient at least one compound of formula: (0 in which • Ri represents a radical selected from-N(R )R5, -N(R4)-CO-R5, and -N(R4)-S02 R6, • R2 and R3, which are identical or different, represent either A) an aromatic group selected from phenyl, naphthyl and indenyl, these aromatic groups being unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, - COOH, COOalk, -CONR7 R8, -CO-NH-NR9 R10, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl and -alk-NR7 Rs radicals; or B) a heteroaromatic group selected from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3- dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic groups to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, COOalk, - CO - NH--NR9 R10, -CONR7 R8) -alk-NR9 R10, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl and hydroxyalkyl, B.4 represents a radical selected from-C(Rn)(R12)--Het, -Het, -(CRn)(R12)--Ar, Ar, cycloalkyl and norbornyl, R5 represents a radical selected from hydrogen, hydroxyalkyl, -alk--COOalk, ~alk~CONR7 Rs, -alk-NR7 R8, alkoxy, Ar, Het, -CH2 Ar, --CH2 Het and alkyl, said radical being optionally substituted with one or more halogens, R6 represents a radical selected from hydroxyalkyl, --alk-COOalk, --alk-CONR7 Rs, --alk-NR7 R8, alkoxy, Ar, Het, -CH2 Ar, -CH2 Het and alkyl, optionally substituted with 1 or more halogens, R7 and Re, which are identical or different, represent a radical selected from hydrogen and alkyl, or, alternatively, R7 and Re together form with the nitrogen atom to which they are attached a 3- or 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a radical selected from hydrogen, alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-0--alk and hydroxyalkyl or, alternatively, R9 and Rio together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2 radicals, Rn represents a radical selected from hydrogen, hydroxyalkyl, -alk--COOalk, -alk-CONR7 R8, -alk-NR7 R8, alkoxyalkyl, Ar, Het, -CH2 Ar, -CH2 Het and alkyl, optionally substituted with one or more halogen atoms, R12 represents a radical selected from hydrogen, hydroxyalkyl, -alk--COOalk, -alk-CONR7 R8, -alk-NR7 R8, alkoxyalkyl and alkyl, optionally substituted with one or more halogen atoms, or alternatively Rn and R12 together form with the carbon atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic ring, optionaDy containing a heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ar represents a phenyl, naphthyl or indenyl radical, these different radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, -CO-alk, cyano, --COOH, -COOalk, --CONR13 R , -CO--NH-NR15 Rie, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NRis Ri6, -NR15 Ri6, alkylthioalkyl, formyl, CF3, OCF3, Het, -0--alk-NH-cycloalkyl, S02 NH2, hydroxyl, hydroxyalkyl, -NHCOalk, and NHCOOalk radicals or, on 2 adjacent carbon atoms, with dioxymethylene, Het represents a 3- or 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, alkoxycarbonyl, oxo or hydroxyl radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form, R13 and R1 , which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R13 and R14 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, i5 and i6, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R15 and Ri6 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, alk represents an alkyl or alkylene radical, • the alkyl and alkylene radicals and portions and the alkoxy radicals and portions being in the form of straight or branched chains and containing 1 to 6 carbon atoms, and the cycloalkyl radicals containing 3 to 10 carbon atoms, • the optical isomers of these compounds and their salts with a pharmaceutically acceptable inorganic or organic acid.
2. A pharmaceutical composition according to claim 1, wherein, in formula (I), Het is a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, cinnoline, thiophene, quinazoline, quinoxaline, quinoline, pyrazole, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, thiadiazole, piperidine, piperazine, triazole, furan, tetrahydroisoquinoline, and tetrahydroquinoline, these heterocycles being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, alkoxycarbonyl, oxo, hydroxyl, OCF3 and CF3 radicals.
3. A pharmaceutical composition according to claim 1. wherein, in the compound of formula (I), • Ri represents a radical selected from -N(R4)R5 and --N(R4)--S02 R6, • R2 represents either A) a phenyl which is unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, -CO--alk, cyano, - CONR7 Re, hydroxylalkyl and -alk-NR7 Rs ; or B) a heteroaromatic ring selected from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic rings to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, -CONR7 Rs, --alk-NRg Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl and hydroxyalkyl, R3 represents either A) a phenyl which is unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, --CO-alk, cyano, -CONR7 Rs, hydroxyalkyl and -alk--NR7 Re ; or B) a heteroaromatic ring selected from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic rings to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy hydroxyl, trifluoromethyl, trifluoromethoxy, --CONR7 Rs, ~alk--NR9 R10, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl and hydroxyalkyl, R4 represents a radical selected from -C(Rn)(R12)-Het, --Het, -C(R11)(R12)-Ar, Ar and norbornyl, R5 represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, -alk-CONR7 Rs, --alk-NR7 R8, alkoxy, -CH2 Ar, ~CH2 Het and alkyl, R6 represents a hydroxyalkyl, -alk-COOalk, -alk-CONR7 R8, -alk--NR7 Rs, alkoxy, -CH2 Ar, -CH2 Het or alkyl radical, R7 and Rs, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R7 and Rs together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a radical selected from hydrogen, alkyl, cycloalkyl, alkylcycloalkyl, -alk-O-alk and hydroxyalkyl or, alternatively, R9 and Rio together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, -COOalk, -CO-NHalk, oxo, hydroxyalkyl or -CO--NH2 radicals, 9 Rn represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, --alk-CONR7 Rs, -alk-NR7 R8, alkoxyalkyl, Ar, Het, -CH2 Ar, -CH2 Het and alkyl, optionally substituted with one or more halogen atoms, Ri2 represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, --alk-CONR7 Re, -alk-NR? Rs, alkoxyalkyl and alkyl, optionally substituted with one or more halogen atoms, Or, alternatively, n and R12 together form with the carbon atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic ring, optionally containing a heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ar represents a phenyl or naphthyl radical, these different radicals being optionally substituted with one or more radicals selected from halogen, alkyl, alkoxy, -CO-alk, cyano, -CONRi3 Ru, alkylsulfonyl, -alk-NRis Ri6, -NR Ri6, CF3, OCF3, SO2 NH2, hydroxyl and hydroxyalkyl, or, on 2 adjacent carbon atoms, with dioxy methylene, Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, thiophene, quinazoline, quinoxaline, quinoline, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, thiadiazole, furan, tetrahydrosoquinoline and tetrahydroquinohne, these heterocycles being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, alkoxycarbonyl, oxo, hydroxyl, OCF3 and CF3 radicals, Ri3 and Ru, which are identical or different, represent a hydrogen or alkyl radical or, alternatively, R13 and R14 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, • Ri5 and R1e, which are identical or different, represent a hydrogen or alkyl radical or, alternatively, R^ and Ri6 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, • the optical isomers of these compounds and their salts with a pharmaceutically acceptable inorganic or organic acid.
4. A pharmaceutical composition according to claim 1, wherein, in the compound of formula (I), • R1 represents a radical -N(R4)--S02 R6, • R2 represents either A) a phenyl which is unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, cyano, -CONR7 Re, hydroxyalkyl and -alk-NR7 Re radicals; or B) a heteroaromatic ring selected from the pyridyl,. pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic rings to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy hydroxyl, trifluoromethyl, tifluoromethoxy, -CONR7 Rs and hydroxyalkyl radicals, • R3 represents either A) a phenyl which is unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, cyano, -CONR7 Re, hydroxyalkyl and -alk-NR7 Rs radicals; or B) a heteroaromatic ring selected from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic rings to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, -CONR7 Rs and hydroxyalkyl, R4 represents --Het or Ar, R6 represents a hydroxyalkyl or alkyl radical, R7 and Re, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R7 and Rs together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ar represents a phenyl or naphthyl radical, these different radicals being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, -CO-alk, cyano, -CONR13 R14, -alk- NR15 R16, -NR15 Ri6, CF3, OCF3, S02 NH2, hydroxyl and hydroxyalkyl radicals, Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, thiophene, quinazoline, quinoxaline, quinoline, pyrrole, pyridine, imidazole, indole, isoquinoline, thiazole, thiadiazole, furan, tetrahydroisoquinoline and tetrahydroquinoline, these heterocycles being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, alkoxycarbonyl, oxo, hydroxyl, OCF3 and CF3, Ri3 and R14, which are identical or different, represent hydrogen an alkyl radical or, alternatively, R13 and R14 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ri5 and Ri6, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, Ri5 and R16 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, • the optical isomers of these compounds and their salts with a pharmaceutically acceptable inorganic or organic acid. composition according to claim 1. wherein the compound of formula (I) elected from the following compounds: • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(6-chloropyrid-2- y 1) methylsulfonamide , • N-{l-[bis(4 -chlorophenyl) methyl] azetidin- 3 -yl} -N- (6 - ethylpyrid-2 - yl) methylsulfonamide , • N- { 1 - [bis (4 -chlorophenyl) methyl] azetidin- 3 -yl} - N- quinol- 6- ylmethylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-quinol-5- ylmethylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-isoquinol-5- ylmethylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-pyrid-3- ylmethylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(l-oxide-pyrid-3- yl) methylsulfonamide, . N-{lR,2S,4S)-bicyclo[2.2. l]hept-2-yl-N-{l-[bis(4- chlorophenyl) methyl] azetidin- 3 -y 1} methylsulfonamide , . N-{lR,2R,4S)-bicyclo[2.2. l]hept-2-yl-N-{l-[bis(4- chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorophenyl)methylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(thiazol-2- yl)methylsulfonamide, • N- { 1 - [bis(4-chlorophenyl)methyl] azetidin- 3-yl}- N-(3- methoxyphenyl)methylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3- hydroxyphenyl)methylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3- hydroxymethylphenyl)methylsulfonamide, • Ethyl N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N- (methylsulf onyl) - 3 - aminobenzoate , • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(l-isobutylpiperid- 4 -yl) methylsulfonamide , • N-benzyl-N-{l-P is(4-chlorophenyl)methyl]azetidin-3-yl}amine, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorobenzyl)amine, • N-{l-Pbis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorobenzyl)methylsulfonamide, • N-{l-[¾is(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3- ylmethyl) methylsulfonamide , • N-{l-[bis(4-fluorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorophenyl) methylsulfonamide , • (RS)-N-{l-[(4-chlorophenyl)pyrid-3-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl) methylsulfonamide , • (R)-N-{l-[(4-chlorophenyl)pyrid-3-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl) methylsulfonamide , • (S)-N-{l-[(4-chlorophenyl)pyrid-3-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl) methylsulfonamide , • (RS)-N-{l-[(4-chlorophenyl)pyrid-4-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl) methylsulfonamide , • (R)-N-{l-[(4-chlorophenyl)pyrid-4-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl)methylsulfonamide, • (S)-N-{l-[(4-chlorophenyl)pyrid-4-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl) methylsulfonamide , • (RS) -N-{ 1 - [(4-chlorophenyl)pyrimidin- 5-ylmethyl] -azetidin- 3 -yl} -N- (3,5- difluoropheny 1) me thylsulfonamide , • (R)-N-{l-[(4-chlorophenyl)pyrimidin-5-ylmethyl]-azetidin-3-yl}-N- (3,5- difluorophenyl) methylsulfonamide, • (S)-N-{l-[(4-chlorophenyl)pyrimidin-5-ylmethyl]-azetidin-3-yl}-N- (3,5- difluorophenyl) methylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorophenyl)benzylsulfonamide, their optical isomers and their pharmaceutically acceptable salts. compound of formula: 0) hich • Ri represents a radical -N(R4)R5, -N(R4)-CO-R5, or -N(R4)-S02 • 2 and R3, which are identical or different, represent either A) an aromatic group selected from phenyl, naphthyl and indenyl, these aromatic groups being unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, - COOH, COOalk, -CONR7 R8, -CO-NH-NR9 Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl and -alk-NR7 Rs radicals; or B) a heteroaromatic ring selected from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3- dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these 105 151321/3 heteroaromatic rings to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, --COOH, COOalk, -CO-NH-NR9 Rio, -CONR7 Rs, -alk-NRg Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl and hydroxyalkyl, R4 represents a radical selected from--C(Rn)(Ri2)--Het, --Het, -(CRn)(Rl2)--Ar, Ar, cycloalkyl and norbornyl, R5 represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, - alk-CONR7 Rs, -alk-NR7 Rs, alkoxy, Ar, Het, -CH2 Ar, -CH2 Het and alkyl, optionally substituted with one or more halogens, R6 represents a hydroxyalkyl, -alk-COOalk, -alk-CONR7 Rs, -alk-NR7 Rs, alkoxy, Ar, Het, -CH2 Ar, -CH2 Het or alkyl radical optionally substituted with 1 or more halogens, R7 and Rs, which are identical or different, represent hydrogenor alkyl radical or, alternatively, R7 and Rs together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a radical selected from hydrogen, alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk and hydroxyalkyl or, alternatively, R9 and Rio together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or --CO-NH2 radicals R11 represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, -alk-CONR7 Rs, -alk-NR7 Rs, alkoxyalkyl, Ar, Het, - CH2 Ar, --CH2 Het and alkyl optionally substituted with one or more halogens, R12 represents a radical selected from hydrogen, hydroxyalkyl, -alk--COOalk, --alk--CONR7 Re, -alk-NR7 Re, alkoxyalkyl or alkyl optionally substituted with one or more halogens, or alternatively Rn and R^ together form with the carbon atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic ring, optionally containing a heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ar represents a phenyl, naphthyl or indenyl radical, these different radicals being optionally substituted with one or more radicals selected from halogen, alkyl, alkoxy, -CO-alk, cyano, --COOH, -COOalk, -CONR13 Ri4, --CO--NH--NR15 Rie, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk--NRi5 Ri6, -NR15 Ri6, alkylthioalkyl, formyl, CF3, OCF3, Het, -0--alk-NH-cycloalkyl, S02 NH2, hydroxyl, hydroxyalkyl, --NHCOalk, and NHCOOalk or, on 2 adjacent carbon atoms, with dioxym ethylene, Het represents a 3- or 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one ore more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, alkoxycarbonyl, oxo and hydroxyl, the rntrogen-contairiing heterocycles being optionally in their N-oxidized form, Ri3 and R14, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R13 and R together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ri5 and Ri6, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R15 and Ri6 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, • alk represents an alkyl or alkylene radical, • the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain containing 1 to 6 carbon atoms and the cycloalkyl radicals contain 3 to 10 carbon atoms, • the optical isomers of these compounds and their salts with a pharmaceutically acceptable inorganic or organic acid, with the exception of benzhydryl-l-cyclopropylamino-3-azetidine dichlorohy drate ; 2 - [2 - (( 1 - (benzhy dr l) - azetidine - 3 -yl) - 2 -amino) - phenyl] -ethanol; and l-diphenylmethyl-3-((2- hydroxymethyl)phenylamino)azetidine, as well as any compound in which R2 and R3 represent phenyl radicals, Ri represents a radical - -N(R )S02 R6 in which R4 represents a phenyl radical and Re represents a methyl radical. 7. A compound of formula (I) according to claim 6. wherein Het is a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, cinnoline, thiophene, quinazoline, quinoxaline, quinoline, pyrazole, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, thiadiazole, piperidine, piperazine, triazole, furan, tetrahydroisoquinoline, and tetrahydroquinoline, these heterocycles being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, alkoxycarbonyl, oxo, hydroxyl, OCF3 and CF3. 8. A compound of formula: (0 wherein • Ri represents a radical -N(R4)R5 or -N(R4)-S02 Re, • R2 represents either A) a phenyl which is unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, - CONR7 Re, hydroxyalkyl and --alk--NR7 Rs radicals; or B) a heteroaromatic ring selected from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic rings to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, -CONR7 R8, -alk--NR9 Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl and hydroxyalkyl, • R3 represents either A) a phenyl which is unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, --CO-alk, cyano, - CONR7 Rs, hydroxyalkyl and -alk-NR7 Rs radicals; or B) a heteroaromatic ring selected from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic rings to be unsubstituted or substituted with a radical selected from halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, -CONR7 Rs, --alk-NRg R10, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl and hydroxyalkyl,R4 represents a radical selected from -C(Rii)(Rl2)-Het, -Het, -C(Rn)(Rl2)--Ar, Ar and norbornyl, • R5 represents a radical selected from hydrogen, hydroxyalkyl, -alk- COOalk, -alk-CONR7 Rs, -alk-NR7 R8, alkoxy, -CH2 Ar, -CH2 Het and alkyl, 109 151321 3 Re represents a hydroxyalkyl, -alk-COOalk, -alk-CONR7 Rs, -a!k»NR7 R8, alkoxy, --CH2 Ar, --CH2 Het or alkyl radical, R7 and Rs, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R7 and s together form with the nitrogen atom to which they are attached a 3- or 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a radical selected from hydrogen, alkyl, cycloalkyl, alkylcycloalkyl, -alk-O-alk and hydroxyalkyl or, alternatively, R9 and R1o together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, "COOalk, -CO--NHalk, oxo, hydroxyalkyl or -CO-NH2 radicals, Ru represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, --alk-CONRv Rs, -alk-NR7 R8, alkoxyalkyl, Ar, Het, -CH2 Ar, -CH2 Het and alkyl optionally substituted with one or more halogen atoms, R12 represents a radical selected from hydrogen, hydroxyalkyl, -alk-COOalk, --alk-CONR7 Rs, -alk-NR7 Rs, alkoxyalkyl and alkyl optionally substituted with one or more halogen atoms, or, alternatively, Ru and R12 together form with the carbon atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic ring, optionally containing a heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ar represents a phenyl or naphthyl radical, these different radicals being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, -CO- alk, cyano, -CONR13 Ru, alkylsulfonyl, »alk~NRi5 Rie, --NR15 Rie, CF3, OCF3, S02 NH2, hydroxyl and hydroxyalkyl radicals or, on 2 adjacent carbon atoms, with dioxymethylene, • Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, thiophene, quinazoline, quinoxaline, quinoline, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, thiadiazole, furan, tetrahydroisoquinoline and tetrahydroquinoline, these heterocycles being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, alkoxycarbonyl, oxo, hydroxyl, OCF3 and CF3 radicals, • R13 and R14, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R13 and R together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, • R15 and Ri6, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R15 and R16 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, the optical isomers of these compounds and their salts with a pharmaceutically acceptable inorganic or organic acid, • with the exception of any compound in which 2 and R3 represent phenyl radicals, Ri represents a radical --N(R4)S02 6 in which R4 represents a phenyl radical and R6 represents a methyl radical; 2- [2-((l-(benzhydryl)-azetidine-3-yl)-2-amino)-phenyl]-ethanol; and 1- diphenylmethyl-3-((2-hydroxymethyl)phenylamino)azetidine. 9. A compound of formula (I) according to claim 8, wherein Ri represents a radical --N(R4)~so2 Re, R2 represents either A) a phenyl which is unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, cyano, -CONR7 Rs, hydroxyalkyl and -alk-NR7 Rs radicals; or B) a heteroaromatic chosen from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, -CONR7 Rs or hydroxyalkyl radical, R3 represents either (1) a phenyl which is unsubstituted or substituted with one or more substituents selected from halogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, cyano, -CONR7 Rs, hydroxyalkyl and -alk-NR7 Rs radicals; or a heteroaromatic ring selected from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic rings to be unsubstituted or substituted with a substituent selected from halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, --CONR7 Rs and hydroxyalkyl, R represents -Het or Ar, Re represents a hydroxyalkyl or alkyl radical, R7 and Rs, which are identical or different, represent hydrogen or an alkyl radical or, alternatively, R7 and Rs together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ar represents a phenyl or naphthyl radical, these different radicals being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, -CO-alk, cyano, -CONR^ R , -alk- NR15 R16, -NR15 R16, CF3, OCF3, SO2 NH2,hydroxyl and hydroxyalkyl radicals, • Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, thiophene, quinazoline, quinoxaline, quinoline, pyrrole, pyridine, imidazole, indole, isoquinoline, thiazole, thiadiazole, furan, tetrahydroisoquinoline and tetrahydroquinoline, these heterocycles being optionally substituted, with one or more substituents selected from halogen, alkyl, alkoxy, alkoxycarbonyl, oxo, hydroxyl, OCF3 and CF3 radicals, • B 3 and R14, which are identical or different, represent hydrogen, or an alkyl radical or, alternatively, Ri3 and r14 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, • Ri5 and R^, which are identical or different, represent hydrogen, or an alkyl radical or, alternatively, R^ and Ri6 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, the optical isomers of these compounds and their salts with a pharmaceutically acceptable inorganic or organic acid, • with the exception of any compound in which R2 and R3 represent phenyl radicals, Ri represents a radical -N(R4)S02 R6 in which R4 represents a phenyl radical and R6 represents a methyl radical. 10. A compound of formula (I) according to claim 8, selected from the following compounds: • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(6-chloropyrid-2- yl)methylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(6-ethylpyrid-2- yl) methylsulf onamide , • N-{1- [bis(4-chlorophenyl)methyl] azetidin-3-yl}-N-quinol-6- ylmethylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-quinol-5- ylmethylsulfonamide , • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-isoquinol-5- ylmethylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-pyrid-3- ylmethylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(l-oxide-pyrid-3- yl) methylsulfonamide , • N-{lR,2S,4S)-bicyclo[2.2. l]hept-2-yl-N-{l-[bis(4- chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide, . N-{lR,2R,4S)-bicyclo[2.2. l]hept-2-yl-N-{l-[bis(4- chlorophenyl) methyl] azetidin- 3 -y 1} methylsulfonamide , • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorophenyl) methylsulfonamide , • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(thiazol-2- yl) methylsulfonamide , • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3- methoxyphenyl) methylsulfonamide , • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3- hy droxyphenyl) methylsulfonamide , • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3- hydroxymethylphenyl)methylsulfonamide, • Ethyl N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N- (methylsulfonyl)-3-aminobenzoate, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(l-isobutylpiperid- 4 -yl) methylsulfonamide, • N-benzyl-N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amine, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorobenzyl)amine, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorobenzyl)methylsulfonamide, • N-{l-|¾is(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3- ylmethyl)methylsulfonamide, • N-{l-|l)is(4-fluorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorophenyl)methylsulfonamide, • (RS)-N-{l-[(4-chlorophenyl)pyrid-3-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl)methylsulfonamide, • (R)-N-{l-[(4-chlorophenyl)pyrid-3-ylmethyl]azetidin-3-yl}-N-(3,5- difluorop he nyl) me thylsulfonamide , • (S)-N-{l-[(4-chlorophenyl)pyrid-3-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl)methylsulfonamide, • (RS)-N-{l-[(4-chlorophenyl)pyrid-4-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl)methylsulfonamide, • (R)-N-{l-[(4-chlorophenyl)pyrid-4-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl)methylsulfonamide , . (S)-N-{l-[(4-chlorophenyl)pyrid-4-ylmethyl]azetidin-3-yl}-N-(3,5- difluorophenyl)methylsulfonamide, • (RS)-N-{l-[(4-chlorophenyl)pyrimidin-5-ylmethyl]-azetidin-3-yl}-N- (3,5-difluorophenyl)methylsulfonamide, • (R)-N-{l-[(4-chlorophenyl)pyrimidin-5-ylmethyl]-azetidin-3-yl}-N- (3,5-difluorophenyl)methylsulfonamide, • (S)-N-{l-[(4-chlorophenyl)pyrimidin-5-ylmethyl]-azetidin-3-yl}-N- (3,5-difluorophenyl)methylsulfonamide, • N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5- difluorophenyl)benzylsulfonamide, their optical isomers and their salts with a pharmaceutically acceptable inorganic or organic acid. 11. N-{l-[bis-(4-chlorophenyl)methyl]- azetidin-3-yl}-N-(3,5-difluoro he nyl)me thylsulfonamide, and its salts with a pharmaceutically acceptable inorganic or organic acid. 12. A process for preparing a compound of formula (I) according to claim 6, for which Β,ι represents a radical -N(R4)R5 in which R5 is a hydrogen atom, R4 is a radical -CRu R12 -Ar or -CRn R12 -Het and R12 is a hydrogen atom, the process comprising reacting a derivative Rb-CORn for which Ru has the same meanings as in claim 6 with a derivative of formula: wherein Rb represents a radical Ar or Het, and R2, R3, R11 Ar and Het have the same meanings as in claim 6, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 13. A process for preparing a compound of formula (I) according to claim 6, for which Ri represents a radical -N(R4)-CO-R5 in which R4 is a radical --C(Rn)(R12)-Het or -C(Rn)(R12)-Ar and R12 is a hydrogen atom, the process comprising reacting a derivative Hal-CORs with a derivative of formula: wherein Hal represents a halogen atom Rb represents a radical Ar or Het, and R2, R3, Rs, R11, Ar and Het have the same meanings as in claim 6, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 14. A process for preparing a compound of formula (I) according to claim 6, for which represents a radical --N(R4)--S02 Re in which R4 is a radical --C(Rn)(Rl2)-Ar or -C(Rn)(R12)-Het and R12 is a hydrogen atom, the process comprising reacting a derivative Hal-S02 Re with a derivative of formula: wherein R2, R3, R11 and R5 have the same meanings as in claim 6, Hal represents a halogen atom and Rb represents a radical Ar or Het, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 1
5. A process for preparing a compound of formula (I) according to claim 6 for which Ri represents a radical -N(R4)R5, the process comprising reacting a derivative R5 (R4)NH with a derivative of formula: wherein, R2, R3, R4 and R5 have the same meanings as in claim 6, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 1
6. A process for preparing a compound of formula (I) according to claim 6 for which R1 represents a radical -N(R4)S02 ]¾, the process comprising reacting a derivative Hal-S02 Re with a derivative of formula: wherein R2, R3, R4 and R6 have the same meanings as in claim 6 and Hal represents a halogen atom, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 1
7. A process for preparing a compound of formula (I) according to claim 6 for which represents a radical -N(R4)COR5, the process comprising reacting a derivative Hal-COR6 with a derivative of formula: wherein R2, R3, R4 and R5 have the same meanings as in claim 6 and Hal represents a halogen atom, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 1
8. A process for preparing a compound of formula (I) according to claim 6 for which Ri represents a radical -N(R4)-S02 --R6 in which R4 is a radical Het or Ar, the process comprising reacting a derivative Rd-NH-S02 -R6 with a derivative of formula: wherein Rd represents a radical Ar or Het; R2, R3 and R6 have the same meanings as in claim 6; and Ms represents a methylsulfonyloxy radical, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 1
9. A process for preparing a compound of formula (I) according to claim 6, the process comprising reacting a derivative R2 -CHBr-R3 with a derivative of formula: wherein Ri, R2 and R3 have the same meanings as in claim 6, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 20. A process for preparing a compound of formula (I) according to claim 6 for which Ri represents a radical -N(R4)-S02 "Re in which R4 is a piperid-4-yl radical substituted on the nitrogen with an alkyl radical, the process comprising alkylating a corresponding compound of formula (I) for which Ri represents a radical --N(R4)-S02 -Re in which R4 is a piperid-4-yl radical, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 21. A process for preparing a compound of formula (I) according to claim 6, for which Ri represents a radical -N(R4)-S02 --Re in which R4 is a phenyl radical substituted with a pyrrolid-l-yl radical, the process comprising reacting pyrrolidine with a corresponding compound of formula (I) in which Ri represents a radical -N(R4)S02 Re for which R4 is a phenyl radical substituted with a halogen atom, isolating the product and optionally converting the product to a pharmaceutically acceptable salt. 22. Use of a compound of formula (I) as defined in claim 6, in the preparation of a medicament for treating or preventing Alzheimer disease. 23. Use of a compound of formula (I) as defined in claim 6, in the preparation of a medicament for treating or preventing Parkinson disease. 24. Use of a compound of formula (I) as defined in claim 6, in the preparation of a medicament for treating or preventing Obesity. 25. Use of a compound of formula (I) as defined in claim 6, in the preparation of a medicament for treating or preventing Schizophrenia.. 26. Use of a pharmaceutical composition as defined in claim 1, in the preparation of a medicament for treating or preventing Alzheimer disease. 27. Use of a pharmaceutical composition as defined in claim 1, in the preparation of a medicament for treating or preventing Parkinson disease. 28. Use of a pharmaceutical composition as defined in claim 1, in the preparation of a medicament for treating or preventing Obesity. 29. Use of a pharmaceutical composition as defined in claim 1, in the preparation of a medicament for treating or preventing Schizophrenia. 30. A compound of formula (I) as defined in claim 6 for use in the treatment of Alzheimer disease. 31. A compound of formula (I) as defined in claim 6 for use in the treatment of Parkinson disease. 32. A compound of formula (I) as defined in claim 6 for use in the treatment of Obesity. 33. A compound of formula (I) as defined in claim 6 for use in the treatment of Schizophrenia. 34. A pharmaceutical composition as defined in claim 1, for use in the treatment of Alzheimer disease. 35. A pharmaceutical composition as defined in claim 1, for use in the treatment of Parkinson disease. 36. A pharmaceutical composition as defined in claim 1, for use in the treatment of Obesity. 37. A pharmaceutical composition as defined in claim 1, for use in the treatment of Schizophrenia. 38. Use of a compound of formula (I) as defined in claim 6, in the preparation of a medicament for treating or preventing Diabetes. 39. Use of a pharmaceutical composition as defined in claim 1, in the preparation of a medicament for treating or preventing Diabetes. 40. A compound of formula (I) as defined in claim 6 for use in the treatment of Diabetes. 41. A pharmaceutical composition as defined in claim 1, for use in the treatment of Diabetes. #611795
IL151321A 2000-03-03 2002-08-18 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof IL151321A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002776A FR2805817B1 (en) 2000-03-03 2000-03-03 PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION
PCT/FR2001/000602 WO2001064634A1 (en) 2000-03-03 2001-03-01 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof

Publications (1)

Publication Number Publication Date
IL151321A true IL151321A (en) 2008-11-03

Family

ID=8847706

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15132101A IL151321A0 (en) 2000-03-03 2001-03-01 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
IL151321A IL151321A (en) 2000-03-03 2002-08-18 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL15132101A IL151321A0 (en) 2000-03-03 2001-03-01 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof

Country Status (36)

Country Link
EP (1) EP1263722B1 (en)
JP (1) JP4883867B2 (en)
KR (1) KR100819572B1 (en)
CN (1) CN100386314C (en)
AT (1) ATE478841T1 (en)
AU (1) AU780880B2 (en)
BG (1) BG66001B1 (en)
BR (1) BR0108893B1 (en)
CA (1) CA2400141C (en)
CY (1) CY1111071T1 (en)
CZ (1) CZ301254B6 (en)
DE (1) DE60142891D1 (en)
DK (1) DK1263722T3 (en)
DZ (1) DZ3312A1 (en)
EA (1) EA007109B1 (en)
EE (1) EE05103B1 (en)
ES (1) ES2351276T3 (en)
FR (1) FR2805817B1 (en)
HR (1) HRP20020712B1 (en)
HU (1) HUP0400636A3 (en)
IL (2) IL151321A0 (en)
MA (1) MA26880A1 (en)
ME (1) MEP9509A (en)
MX (1) MXPA02008349A (en)
NO (1) NO324524B1 (en)
NZ (1) NZ521077A (en)
OA (1) OA12222A (en)
PL (1) PL208021B1 (en)
PT (1) PT1263722E (en)
SI (1) SI1263722T1 (en)
SK (1) SK287445B6 (en)
TW (1) TWI304399B (en)
UA (1) UA73554C2 (en)
WO (1) WO2001064634A1 (en)
YU (1) YU66002A (en)
ZA (1) ZA200206912B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022579A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
FR2814678B1 (en) * 2000-10-04 2002-12-20 Aventis Pharma Sa COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
FR2833842B1 (en) * 2001-12-21 2004-02-13 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
RU2304580C2 (en) 2002-07-29 2007-08-20 Ф.Хоффманн-Ля Рош Аг Novel benzodioxols
PL378244A1 (en) 2003-01-02 2006-03-20 F. Hoffmann-La Roche Ag Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists
WO2004060870A1 (en) 2003-01-02 2004-07-22 F. Hoffmann-La Roche Ag Novel cb 1 receptour inverse agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1601665A2 (en) * 2003-03-07 2005-12-07 Glaxo Group Limited Urea derivatives
JP2006525297A (en) * 2003-05-01 2006-11-09 ヴァーナリス リサーチ リミテッド Use of azetidine carboxamide derivatives in therapy
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
ES2303077T3 (en) 2003-06-20 2008-08-01 F. Hoffmann-La Roche Ag 2-AMINOBENZOTIAZOLES AS INVESTED AGONISTS OF THE CB1 RECEIVER.
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
CN100509808C (en) 2003-12-08 2009-07-08 霍夫曼-拉罗奇有限公司 Novel thiazole derivates
EP1716132B1 (en) 2004-01-28 2010-08-25 F. Hoffmann-La Roche AG Spiro-benzodioxoles and their use as cb1 antagonists
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
JP2007536298A (en) 2004-05-10 2007-12-13 エフ．ホフマン−ラ　ロシュ　アーゲー Pyrrole or imidazole amide for the treatment of obesity
FR2876688B1 (en) * 2004-10-14 2007-03-16 Aventis Pharma Sa NEW PRODUCT, PROCESS AND INTERMEDIATES FOR PREPARING AZETIDINE DERIVATIVES
FR2876689B1 (en) * 2004-10-14 2008-02-22 Aventis Pharma Sa NOVEL PROCESS AND INTERMEDIATES FOR PREPARING N- (1-BENZHYDRYL-AZETIDIN-3-YL) -N-PHENYL-METHYLSULFONAMIDE DERIVATIVES
ES2309812T3 (en) 2004-10-27 2008-12-16 F. Hoffmann-La Roche Ag NEW DERIVATIVES OF INDOL OR BENZIMIDAZOL.
EP1812418B1 (en) 2004-11-09 2010-10-27 F. Hoffmann-La Roche AG Dibenzosuberone derivatives
DE602006007563D1 (en) 2005-04-06 2009-08-13 Hoffmann La Roche AGONIST
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
CA2619770A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
JP4371164B2 (en) 2005-11-10 2009-11-25 萬有製薬株式会社 Aza-substituted spiro derivatives
AR058199A1 (en) * 2005-11-28 2008-01-23 Merck & Co Inc DERIVATIVES OF 3- RENTED ALQUILAZETIDINA WITH HETEROCICLOS
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (en) 2006-09-28 2010-01-28 萬有製薬株式会社 Diaryl ketimine derivatives
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
FR2925050B1 (en) * 2007-12-14 2010-01-08 Sanofi Aventis NEW PROCESS FOR THE PREPARATION OF AZETIDINE DERIVATIVES
EA019315B1 (en) * 2007-12-18 2014-02-28 Санофи-Авентис Azetidine derivatives, their preparation and their application in therapy
FR2930941B1 (en) * 2008-05-06 2010-06-18 Sanofi Aventis AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2928149B1 (en) 2008-02-29 2011-01-14 Sanofi Aventis AZETIDINE-DERIVED COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
JPWO2009154132A1 (en) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 Spirodiamine-diarylketoxime derivatives
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
FR2934996B1 (en) * 2008-08-14 2010-08-27 Sanofi Aventis AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
FR2934995B1 (en) * 2008-08-14 2010-08-27 Sanofi Aventis POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5635991B2 (en) 2008-10-30 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Isonicotinamide orexin receptor antagonist
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
FR2946650B1 (en) * 2009-06-16 2011-08-19 Sanofi Aventis ESTERS DERIVED FROM AZETIDINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS.
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
JP2013520502A (en) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション Novel cyclic benzimidazole derivatives that are useful anti-diabetic drugs
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (en) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents.
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
MX2015001500A (en) 2012-08-02 2015-04-08 Merck Sharp & Dohme Antidiabetic tricyclic compounds.
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
RS65632B1 (en) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
TWI767945B (en) 2016-10-14 2022-06-21 義大利商Ｔｅｓ製藥（股份）責任有限公司 INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
TW202045476A (en) 2019-02-13 2020-12-16 美商默沙東藥廠 5-alkyl pyrrolidine orexin receptor agonists
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CN116249697A (en) 2020-08-18 2023-06-09 默沙东有限责任公司 Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
FR2649100B1 (en) * 1989-06-29 1994-03-04 Laboratorios Dr Esteve Sa NOVEL AZETIDINES, THEIR PREPARATION AND THEIR APPLICATION AS INTERMEDIATES FOR THE PREPARATION OF COMPOUNDS WITH ANTIMICROBIAL ACTIVITY
US5556861A (en) * 1991-10-01 1996-09-17 Laboratoire Roger Bellon 1,8 benzonaphthyridine derivatives and antimicrobial compositions
CA2166975C (en) * 1993-07-16 2005-04-05 Mark G. Bock Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US6022868A (en) * 1995-06-29 2000-02-08 Novo Nordisk Als Substituted azacyclic or azabicyclic compounds
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Also Published As

Publication number Publication date
SK287445B6 (en) 2010-10-07
AU3752701A (en) 2001-09-12
EP1263722A1 (en) 2002-12-11
HUP0400636A2 (en) 2004-06-28
ES2351276T3 (en) 2011-02-02
NO20024177D0 (en) 2002-09-02
BR0108893A (en) 2002-11-05
PL365046A1 (en) 2004-12-27
JP4883867B2 (en) 2012-02-22
AU780880B2 (en) 2005-04-21
BG107058A (en) 2003-07-31
PL208021B1 (en) 2011-03-31
UA73554C2 (en) 2005-08-15
EP1263722B1 (en) 2010-08-25
KR20020075469A (en) 2002-10-04
CN100386314C (en) 2008-05-07
ZA200206912B (en) 2003-11-03
EA200200938A1 (en) 2003-02-27
CZ301254B6 (en) 2009-12-23
CN1418192A (en) 2003-05-14
ATE478841T1 (en) 2010-09-15
OA12222A (en) 2006-05-10
HRP20020712B1 (en) 2012-11-30
DE60142891D1 (en) 2010-10-07
SI1263722T1 (en) 2010-12-31
CY1111071T1 (en) 2015-06-11
MXPA02008349A (en) 2002-12-13
NZ521077A (en) 2004-09-24
EE05103B1 (en) 2008-12-15
DK1263722T3 (en) 2011-01-03
EE200200485A (en) 2004-02-16
HRP20020712A2 (en) 2005-10-31
YU66002A (en) 2005-09-19
DZ3312A1 (en) 2001-09-07
TWI304399B (en) 2008-12-21
BG66001B1 (en) 2010-09-30
MA26880A1 (en) 2004-12-20
WO2001064634A1 (en) 2001-09-07
IL151321A0 (en) 2003-04-10
SK12432002A3 (en) 2003-06-03
CA2400141C (en) 2012-02-21
JP2003525270A (en) 2003-08-26
NO20024177L (en) 2002-10-29
PT1263722E (en) 2010-11-23
KR100819572B1 (en) 2008-04-04
FR2805817B1 (en) 2002-04-26
NO324524B1 (en) 2007-11-12
FR2805817A1 (en) 2001-09-07
HUP0400636A3 (en) 2004-09-28
CA2400141A1 (en) 2001-09-07
BR0108893B1 (en) 2013-06-04
EA007109B1 (en) 2006-06-30
MEP9509A (en) 2011-12-20

Similar Documents

Publication Publication Date Title
IL151321A (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
US6355631B1 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6734176B2 (en) Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
AU2001237526B2 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
US6872717B2 (en) Pharmacological uses of azetidine derivatives
AU2001237525B2 (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees